



Review article

Past, Present, and Future of Affinity-based Cell Separation Technologies

Kaitlyn Bacon^{a,†}, Ashton Lavoie^{a,†}, Balaji M. Rao^{a,c}, Michael Daniele^b, Stefano Menegatti^{a,c,*}^a Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC 27695-7905, USA^b Joint Department of Biomedical Engineering, North Carolina State University – University of North Carolina Chapel Hill, North Carolina, United States^c Biomanufacturing Training and Education Center (BTEC), North Carolina State University, Raleigh, NC 27695-7928, USA

ARTICLE INFO

Article history:

Received 27 March 2020

Revised 29 April 2020

Accepted 5 May 2020

Available online 19 May 2020

Keywords:

Cell purification

Immunoaffinity

MACS

FACS

Microfluidics

ABSTRACT

Progress in cell purification technology is critical to increase the availability of viable cells for therapeutic, diagnostic, and research applications. A variety of techniques are now available for cell separation, ranging from non-affinity methods such as density gradient centrifugation, dielectrophoresis, and filtration, to affinity methods such as chromatography, two-phase partitioning, and magnetic-/fluorescence-assisted cell sorting. For clinical and analytical procedures that require highly purified cells, the choice of cell purification method is crucial, since every method offers a different balance between yield, purity, and bioactivity of the cell product. For most applications, the requisite purity is only achievable through affinity methods, owing to the high target specificity that they grant. In this review, we discuss past and current methods for developing cell-targeting affinity ligands and their application in cell purification, along with the benefits and challenges associated with different purification formats. We further present new technologies, like stimuli-responsive ligands and parallelized microfluidic devices, towards improving the viability and throughput of cell products for tissue engineering and regenerative medicine. Our comparative analysis provides guidance in the multifarious landscape of cell separation techniques and highlights new technologies that are poised to play a key role in the future of cell purification in clinical settings and the biotech industry.

Statement of significance

Technologies for cell purification have served science, medicine, and industrial biotechnology and biomanufacturing for decades. This review presents a comprehensive survey of this field by highlighting the scope and relevance of all known methods for cell isolation, old and new alike. The first section covers the main classes of target cells and compares traditional non-affinity and affinity-based purification techniques, focusing on established ligands and chromatographic formats. The second section presents an excursus of affinity-based pseudo-chromatographic and non-chromatographic technologies, especially focusing on magnetic-activated cell sorting (MACS) and fluorescence-activated cell sorting (FACS). Finally, the third section presents an overview of new technologies and emerging trends, highlighting how the progress in chemical, material, and microfluidic sciences has opened new exciting avenues towards high-throughput and high-purity cell isolation processes. This review is designed to guide scientists and engineers in their choice of suitable cell purification techniques for research or bioprocessing needs.

© 2020 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

1. Introduction

The ability to sort cells into distinct, mono-disperse populations is crucial to advance our knowledge of specific phenotypes, and explore their potential in tissue engineering and regenerative medicine [1,2]. Efficient cell separation is therefore paramount in a

multitude of fields, including personalized cell therapy [3–6], organ recellularization [7–11], diagnostics and disease monitoring [12–17], drug discovery [18–22], and basic cell biology [23–25]. To meet the growing demand for highly pure cell products, there has been considerable effort to develop efficient and high-throughput separation methods. As a result, a multitude of techniques have emerged, which are classified into separations by (i) physical characteristics (i.e., cell volume and shape, density, and light scatter properties or fluorescence), (ii) surface properties (i.e., electrical charges, hydrophobicity, etc.) and cell constituents (i.e., such as nucleic acids,

* Corresponding author: phone: (919) 515 6398.

E-mail address: smenega@ncsu.edu (S. Menegatti).

† denotes equal contribution.




Fig. 1. Cell properties and corresponding purification techniques.




Fig. 2. Cell purification technologies.

enzymes and other proteins), and (iii) adherence/affinity features [26–29] (Fig. 1).

When supplying cells for therapeutic applications, separation technologies must meet analytical benchmarks and regulatory compliance [30–32]. Consistency in product quality, in terms of cell viability and phenotype purity, is highly controlled to ensure product efficacy and patient safety [33–35]. The presence of adventitious agents is also rigorously monitored, and all processing steps must be compatible with sterility requirements [33,36,37].

Affinity-based separations have emerged as the main technology for cell isolation, as they meet the demand for high yield and purity, together with scalability and sterility [27,38]. After three decades of developments, however, a systematic review is needed to recapitulate the diversity and complexity of affinity-based cell separation technologies and guide new users through the selection of appropriate purification methods. To this end, we present a comprehensive survey of affinity-based methods for cell purification, including traditional chromatographic techniques to more recent, non-chromatographic or pseudo-chromatographic systems (Fig. 2, Table 1). These methods employ a variety of biorecognition agents for capture, ranging from traditional protein ligands to synthetic binders. Through this comparison, we also aim to identify emerging opportunities for improving the manufacturing of cells for tissue engineering and regenerative medicine.

2. Cells of interest

A list of clinically relevant cell products is provided in Fig. 3. The isolation of erythrocytes is a prerequisite for estimating erythrocyte aging [39] and diagnosing conditions such as anemia [40] as well as vascular [41] and neurodegenerative diseases (Alzheimer's and Parkinson's) [12,42]. Similarly, the isolation of lymphocytes is needed when assessing immune activation [13,14], and as such, these cells are valuable in diagnosing or studying HIV infections [43], autoimmune diseases [44], post-operative infections [45], transplant rejection [46], and graft-versus-host disease (GvHD) [47,48]. Mast cells (MCs) also represent a relevant

class of targets, especially for studying innate immune response, as their specific role *in vivo* is still unclear; while often associated with allergic response, specifically anaphylaxis, and hypersensitivity reactions [49,50], MCs have also been found to have significant roles in a host's defense against infections [51–53], angiogenesis during pregnancy [54], wound healing [55,56], and autoimmune diseases [57]. Obtaining pure mast cell isolates has the potential to greatly improve our knowledge of disease mechanisms through the study of mast cell activation and immune response stimulation [58,59]. Stem and progenitor cells are key ingredients in regenerative medicine and developmental biology, where they are used to reconstruct decellularized organs or to seed scaffolds for tissue and organ engineering [7,9,60]. For these reasons, stem cells have shown promise to help relieve the shortage of transplant organs [61,62], to treat a number of conditions including macular degeneration [63] and Parkinson's disease [64,65], or as a therapy to repopulate heart tissue after myocardial infarction [66,67]. The isolation of stem cells involves an additional challenge compared to common cell purification, as undifferentiated cells must be removed prior to implantation to reduce the risk of teratoma formation [68,69]; with an average of 10^7 – 10^9 cells being required for a transplant [70,71], even a 0.1% impurity level can result in a load of 10^6 undifferentiated cells and teratoma formation [72,73]. Several technologies have been developed for stem cell purification based on cell phenotype, including density-gradient separation [74,75], fluorescence-activated cell sorting (FACS) [73,76,77], and metabolic selection [78]. Improved cell purification techniques would also be beneficial to detect and monitor circulating tumor cells [79,80] and pathogen infections [81]. It is in fact particularly difficult to isolate circulating tumor cells due to their rarity (~ 1 circulating tumor cell per 10^8 red blood cells [82]). Additionally, cell separation techniques have been used to remove virus-infected cells from a patient to reduce their overall viral load, as shown with malaria and hepatitis C [83–87]. Improved pathogen infection detection is not only beneficial for human related infections like those caused by HIV [88,89], but also for the monitoring of food-related pathogens [90–92].

Table 1
Comparison of physical (non-affinity) and affinity-based cell separation techniques.

Method		Mechanism	Target cells	Advantages	Disadvantages	Negative Enrichment	Scalability	Ref.
Physical (non-affinity) methods								
Density gradient centrifugation		Cells migrate through a vertical density gradient (aqueous solutions of biopolymers) during centrifugation and collect in the region where the local density corresponds to their own.	Human mesenchymal stem cells, hematopoietic stem and progenitor cells, blood cells (erythrocyte, platelets, granulocytes, lymphocytes, monocytes), circulating tumor cells, sperm cells, and neurons. Rat pancreatic islets.	Label-free technology, which enables processing large volumes in short process times and concentrating the cell product; high viability of the cell product; reproducible results; facile scale up; commercially available equipment.	Requires knowledge of the density of the different cells in the mixture; low recovery and poor separation of target from non-target cells (low purity); labor intensive.	*	Yes	75, 94, 95, 97, 101
Dielectrophoresis		Cells placed in a gradient electric field act as induced dipoles and migrate at different rates based on their size and dielectric properties as well as the dielectric properties of the medium.	Hematopoietic stem and progenitor cells, leukocytes (B and T-lymphocytes, monocytes, and granulocytes), circulating tumor cells, astrocyte and neuron-biased cells, and neural stem and progenitor cells. Isolation of pathogenic bacteria from blood. Fractionation of viable vs. non-viable cells (yeast and mammalian cells).	Label-free, continuous technology that enables sorting cells based on viability without dilution, thereby reducing sample volumes; short processing time and high sensitivity; can be integrated with microfluidic devices.	Inadequate for highly complex mixtures where differences in dielectric properties may not be sufficient to enable efficient separation of target cells from unwanted cell types; cell viability can also be significantly decreased after exposure to electric field or overheating, which complicates fabrication and can induce cell differentiation.	*	No	102, 104, 105
Field flow fractionation		A cell suspension is flown through a channel where a field (e.g., crossflow, sedimentation, and electrical) is applied perpendicular to the direction of flow enabling separation based on mobility differences.	Pathogenic bacteria and yeast cell subpopulations. Human blood cells (erythrocyte, platelets, leukocytes), cancer cells, neurons from cerebral cortices, embryonic stem cells, mesenchymal stem cells, hematopoietic stem cells, electroporated vs. non-electroporated cells, and cells undergoing apoptosis.	Label-free, continuous technology that grants high viability and bioactivity of the cell product under short process time; reduced sample volumes; high reproducibility.	Requires dilution of the cell sample prior to separation to avoid cell aggregation and provides limited yield of target cells; unclear criteria for the decision of the field to apply for separation; limited availability of commercial equipment.	Yes	Yes	106,110, 111
Filtration		Cells are captured non-specifically on the surface of a material with controlled porosity based on physical properties such as cell diameter (volume) and aspect ratio. Generally used as preparative tool for further purification.	Blood cells (leukocytes, erythrocytes), hematopoietic stem and progenitor cells, adipose-derived stem cells, mesenchymal stem cells, and circulating tumor cells. Bacterial and mammalian (e.g., Chinese Hamster Ovary (CHO) cells) cells for metabolomics preparation.	High-throughput, simple, scalable technology, which can be integrated into a microfluid device platform.	Low-to-medium yield; potential for the filter to clog; likelihood of cell damage caused by the high flow rates and pressures.	*	Yes	112, 114–116, 118
Elutriation centrifugation		Cells are separated based on their sedimentation velocity.	Blood cells (granulocytes, lymphocytes, monocytes, platelets), macrophages, Kupffer cells from liver, mast cells, hepatocytes, sperm cells (rats and human), separation into age-related fractions (yeast, erythrocytes), prostate and ovarian cancer cells from tumors, and hematopoietic stem and progenitor cells.	Rapid processing of large volumes of cells featuring a wide range of sizes; applicability at low temperatures to impede cell activation; high recovery and viability of the cell product.	Highly labor intensive (mitigated by impeller); difficult separation of cells featuring similar sedimentation properties; high cost of specialized rotors.	*	Yes	120–123
Affinity-based methods								
Rosetting		Antigen-specific cells are incubated with antigen-coated erythrocytes, with which they aggregate into "rosettes" that can be separated by gradient centrifugation.	Human B and T lymphocytes, and mesenchymal stem cells (negative selection).	Commercial products available; high cell bioactivity and purity.	Expensive, complex, slow procedure that requires multiple reagents; when performing positive selection, lysis of the erythrocytes is required to isolate the target cells.	Yes	No	222, 223
Chromatography-based (cell affinity chromatography, CAC)	Packed beds	The cell suspension is flown through a packed bed of ligand-functionalized porous particles. Target cells are captured on the surface of the pores, washed, and finally eluted.	Human T lymphocytes (CD3 ⁺ , CD4 ⁺ , and CD8 ⁺), B lymphocytes (CD19 ⁺ cells), monocytes and granulocytes (CD14 ⁺ cells), and umbilical vein endothelial cells (CD31 ⁺).	Large availability of commercial affinity-based adsorbents; simple operation.	Diffusion limitations; cells are too large to enter pores of beads; difficult elution of captured cells in viable form; shear stress on cells.	Yes	Yes	203, 206, 229
	Fluidized beds	A cell suspension is fed upward to agitate/suspend ligand-functionalized porous particles. Target cells are captured on the surface of the beads, washed, and finally eluted.	Yeast cells. Human monocytes and erythrocytes.	Improved mass transfer; large inter-particle volume; and high surface area.	Shear stress on cells; need for large columns; long equilibration times; non-specific capture by the adsorbent matrix; narrow range of appropriate flow velocities; difficult elution; fouling; diffusion limitations.	Yes	Yes	215, 264, 266
	Cryogels	A cell suspension is flown through a continuous, macroporous matrix prepared by gelation-polymerization at sub-freezing temperatures. Target cells can be captured by affinity ligands conjugated to the matrix, and eluted either via traditional methods (buffer with controlled pH) or via thermal/mechanical compression of the matrix.	Bacterial cells and yeast. Human B lymphocytes, hematopoietic stem and progenitor cells, and human acute myeloid leukemia KG-1 cells (CD34 ⁺).	Mechanical softness of the substrate, reduced shear stress, and elution by stimuli responsive matrix compression enable high viability of mammalian cell products; pore size appropriate for cells of varying size (1–15 μm); extended life cycle; reduced diffusion limitations and fouling due to convective flow; high storage stability.	Modest cell purity and recovery; the affinity ligands remain bound to cell when eluting via matrix compression.	Yes	Yes	199, 228, 269, 279
Pseudo-chromatographic	Gel separation	A cell suspension is flown through a macroporous hydrogel, where target cells are captured by affinity, washed, and later released by dissolving the gel via thermal or enzymatic degradation.	Human spleen cells, and B and T lymphocytes.	High yield and bioactivity of the target cells owing to gentle elution conditions.	The affinity tag remains bound to the cell; the adsorbent is non-reusable.	*	Yes	211, 296, 297
	Fibers	A cell suspension is flown through an array of hollow fibers, where target cells are captured by affinity binding, washed, and later released by mechanical, chemical (e.g., controlled pH or reducing agents), or enzymatic treatments.	Human T lymphocytes (CD4 ⁺), hematopoietic stem and progenitor cells (CD34 ⁺), spleen cells, erythrocyte subpopulations, and cancer cells.	The flow rate through the hollow fiber can be used to tune cell binding strength and elution; no diffusional limitations; the matrix is affordable and available at large scale; can be regenerated; possible integration in microfluidic platforms.	Low binding capacity; considerable cell disruption by shear; non-specific binding to fiber.	Yes	Yes	301, 302, 306
	Membranes	A cell suspension is adsorbed onto a fibermat/membrane, where target cells are captured by affinity binding, washed, and later released via non-specific or competitive elution.	Mouse CD80 ⁺ transfected cells. Human acute myeloid leukemia cells (CD34 ⁺), B lymphocytes, T lymphocytes (CD4 ⁺), MCF-7 cells (EpCAM ⁺), and PC3 prostate cancer cells (EpCAM ⁺).	High throughput (owing to high flow rates and no diffusion limitations); cell elution via flow-/bubble-induced cell detachment; control of flux and fluid velocity enable optimization of adsorption, elution, and fouling; possible thermo-responsive elution; possible integration into microfluidic platforms.	Modest binding capacity due to low specific surface area; high shear stress on cells; modest purity due to non-specific interactions of the cells with membrane surface; current methods of thermo-responsive elution require additional purification to remove the ligand.	Yes	Yes	309–314
Non-chromatographic	ATPS	Cells undergo differential migration across the interface between two immiscible polymer solutions based on the properties of the layers and polymer-bound ligands.	Hybridoma cells. Human acute myeloid leukemia cells (CD34 ⁺), hematopoietic stem and progenitor cells (CD34 ⁺), and CD133 ⁺ stem cells.	Provides high viability of the cell product by minimizing mechanical shear; potential incorporation of stimuli-responsiveness into polymers to promote gentle elution, biocompatibility, short process time, and recycling of the affinity ligands.	Modest recovery and purity; need of separating the target cells from phase-forming polymer after extraction; may require repetitive extractions to achieve sufficient selectivity; difficult to predict how cells will partition based on their physical properties; the interface may be instable.	*	Yes	315, 320, 326, 328
	MACS	Target cells are captured on the outer surface of magnetic nanoparticles, which are separated from the feedstock using a magnet. Following washing, particle-bound cells are eluted via chemical, enzymatic or competitive mechanism.	Pathogenic bacteria. Human B type acute lymphoblastic leukemia cells (CD19 ⁺ , CD45 ⁺), monoblastic leukemia cells U937 (CD34 ⁺), B cell lymphocytes (CD19 ⁺), T cell lymphocytes (CD4 ⁺ , CD8 ⁺), circulating tumor cells (EpCAM ⁺), hematopoietic stem and progenitor cells (CD34 ⁺), mesenchymal stem cells (CD90 ⁺), and megakaryocytic cells (CD61 ⁺).	High recovery and purity of target cells; rapid; commercially available immunomagnetic beads; facile automation and integration with other separation techniques.	Harsh elution conditions; low binding capacity; sorting limited to a single surface marker; cannot sort based on expression density; non-specific binding to magnetic bead surface; can trigger cell differentiation.	Yes	#	338, 339, 341, 344, 345
	FACS	Cells tagged with fluorescent ligands are encapsulated into single-cell droplets, which are flown through a detection zone and charged based on their fluorescence. The charged droplets (target cells) fall through electrostatic deflecting plates and are sorted based on their charge.	Neural stem cell subpopulations (CD56, CD133, FORSE-1, SSEA-1, TRA-1-80, etc), undifferentiated embryonic stem cells (SSEA-4 ⁺ , TRA-1-60 ⁺), hematopoietic stem cells (CD34 ⁺ , CD59 ⁺ , Thy1 ⁺ , CD38 ^{low} , c-Kit ^{low} , lin ⁺), T cell lymphocytes (CD4 ⁺ , CD8 ⁺), antigen-specific B lymphocytes, circulating tumor cells (EpCAM ⁺ , p75NTR ⁺), and skeletal muscle stem cells (VCAM ⁺ CD31 ⁺ CD45 ⁺ Sca1 ⁺).	Highly pure cell product; enables cell counting; rapid separation; allows single cell analysis; can sort using multiple surface markers; can sort cells into high-/low-expression populations.	Low throughput; affinity labels remain adsorbed on the surface of the cells; requires low cell concentration; cannot ensure cell sterility; expensive equipment that requires trained operators and long process time.	*	No	220, 373, 374, 384
	Microfluidics	Capture of cells through a combination of affinity-based and field flow-based techniques framed within microfluidic devices.	Mouse adipose-derived stem cells (negative depletion), Human circulating tumor cells (positive or negative enrichment), endothelial progenitor cells (CD34 ⁺ , VEGFR-2 ⁺ , CD31 ⁺ , CD146 ⁺), neutrophils (CD64 ⁺ , CD66b ⁺), hematopoietic stem and progenitor cells (CD34 ⁺), and T cell lymphocytes (CD4 ⁺ , CD8 ⁺).	Highly precise and sensitive cell separation resulting in high purity of the cell product; can perform multiple functions and/or combine multiple separation methods in one device; efficient phenotype isolation especially for rare cell types; analysis of small sample volumes and single-cell manipulation; facile automation and realization of point-of-care testing.	Low throughput; potentially expensive fabrication; limited lifespan due to clogging; may require complex sample preparations; high user-to-user variation.	Yes	#	381, 386, 388, 389, 396, 399




Fig. 3. Cell targets and their diagnostic or therapeutic applications.

3. Non-affinity methods

Outside of affinity-based methods, cell separation is typically based on the physical properties of cells [93,94]. These methods include density gradient centrifugation [95–100], dielectrophoresis [101–105], field-flow fractionation [102,106–111], filtration [112–118], and elutriation centrifugation [119–123]. While useful for primary enrichment, these methods lack the specificity and resolution to achieve the levels of purity required for therapeutic and analytical applications [93,94,124,125], and typically afford low yield for rare cell types [107,126]. To overcome these limitations, affinity-based methods have been implemented to improve recovery and purity [29,127–131]. These rely on the specific recognition and binding of a cell surface target by a complementary molecule, called *ligand*, immobilized on a suitable carrier or surface [132,133]. Protein ligands, especially antibodies, are currently the major workhorse in affinity-based cell purification, owing to their high capture strength and selectivity [134–137]. Biological ligands, however, are expensive and often suffer from low biochemical stability. Furthermore, their strong binding often makes the elution of cells challenging [133,138,139]. Thus, improvements in affinity methods are needed to enable therapeutic and analytical approaches that rely on consistent and cost-effective cell purification. The main channels of innovation are (i) the identification of cost-effective synthetic affinity or pseudo-affinity ligands for replacing biological ligands, (ii) the development of purification formats that improve upon classic chromatography originally designed for protein purification, and (iii) the determination of unique surface receptors on the target cells that are appropriate for use as affinity targets to ensure high phenotypical purity of the cell product.

4. Conventional Affinity Ligand Formats and Selection for Cell Separation

In cell separations, ligands bind proteins that are ideally unique or overexpressed on the cell membrane of the population of interest. Three ligand families are currently the most employed in cell separation: antibodies, proteins, and lectins. More recently, however, novel synthetic ligands have emerged as promising and cost-effective alternatives. In this section, conventional ligands used for cell separation are described as well as the desired ligand properties to achieve successful cell purification.

4.1. Cell properties that determine the outcome of affinity-based cell purification

Cell sorting relies on the identification of a target receptor on either the cell phenotype of interest (positive cell enrichment) or the background cells (negative cell enrichment) [13,14,140,141], based on the target's abundance on the cell surface, the hetero-

geneity of cell population, and the requirements for the final cell product [142–144]. Typically, each receptor forms only $\sim 0.01\%$ of the total membrane protein content [145,146], although proteins considered of “low-abundance” can be considerably less, as occurs on T or B lymphocytes [147]. The difficulty in identifying unique biomarkers for a target cell phenotype complicates the separation process and renders the assessment of cell product purity challenging [140,148–150]. Cell surface receptors may vary among donors and different tissues isolated from an individual donor [151–153]. This heterogeneity complicates the selection of target cell markers for affinity purification and has slowed considerably the study of certain cell classes. This has particularly been the case for mast cells [51,53,56], whose purification by affinity is predominantly based on CD117 (c-Kit) targeting, although this receptor is not specific to mast cells and is present in many stem cell phenotypes [154]. For target cells featuring a particularly low surface density of unique receptors, negative enrichment is the preferred strategy [13,155–157]. When low expression level is combined with low target cell abundance, microfluidic devices integrating negative selection strategies and physical separation methods (e.g., fluid, electric, or magnetic field) represent the technology of choice [156,158–160].

Additional considerations when selecting the target receptor come from the biochemical effects that occur upon receptor binding. External cell receptors are inherently connected to cell metabolism, and ligand/receptor interactions can trigger undesired events such as internalization of the receptor, metabolic alteration, and even differentiation, in the case of stem cells [151,152,161]. Metabolic changes caused by affinity binding have been observed on mast cells enriched by targeting c-kit and FcεRI; while utilized for the positive selection of mast cells, these markers are crucial in IgE activation and are likely to impact cellular metabolism [58,162].

Ligand selection must also take into account both kinetic (k_{on} and k_{off}) and thermodynamic (K_D) binding parameters [163–166]. Binding strength (K_D) is crucial to ensure product purity, and, in the case of positive selection, to ensure that the target cells can be eluted from the affinity adsorbent. High-affinity ligands (low K_D), while binding target cells specifically, make cell elution difficult, whereas low-affinity ligands (high K_D), while allowing for easier elution, may not provide sufficient throughput. Thus, an ideal affinity ligand offers a balance between specific binding and effective elution [133]. Furthermore, quantifying cell adsorption in terms of K_D only is not accurate, due to multi-point interactions between a target cell and multiple immobilized ligands known as avidity. Cell size, aspect ratio, and receptor density can be used to estimate the number of interactions per cell, and to select an appropriate ligand density for a given value of K_D [167,168]. Finally, cell elution conditions are also crucial, as they strongly affect the viability of the recovered cells [138]. Elution can be achieved (i) non-specifically, by manipulating the salt concentration, pH, or temperature, or (ii)




Fig. 4. Cell immunoaffinity chromatography. (A) Contacting a mixture of cells with the affinity substrate (e.g., an immunoaffinity adsorbent); (B) Removing the unbound cells by washing; (C) Eluting the target cell.

specifically, by using eluents that inhibit the ligand-cell interactions [139,140]. Non-specific methods can damage the cells, while specific methods tend to be expensive. To overcome these issues, specific elution methods using multivalent competitive inhibitors have been presented, which have shown increased cell recovery compared to monovalent inhibitors [139,169].

4.2. Antibodies

“Immunoaffinity”, i.e. the use of antibodies as affinity ligands (Fig. 4), has been widely applied for cell purification, owing to the antibodies’ binding selectivity and ability to operate effectively under physiological conditions [93,150,170–175]. Following the seminal work by Peterson [176] and Wigzell [177,178], immunoaffinity has been employed to purify a wide variety of cells, including pathogenic bacteria [179], lymphocytes [180–185], mast and inflammatory cells [186,187], neural cells [188,189], and stem cells [190–192]. Recently, antibody fragments, such as Fabs and scFvs, have been utilized as ligands in lieu of whole antibodies, as they possess the same binding activity while being produced more affordably [193,194]. The strength of the interaction between the antibody and target protein, however, requires harsh elution conditions that may impact the cells’ viability. To address this issue, elution strategies have included competitive elution [181,195,196] and cleavable linkers [197,198].

4.3. Protein A/G

Another antibody-based method for cell isolation relies on Protein A and Protein G, two antibody-binding proteins expressed respectively by *Staphylococcus aureus* and group C and G *Streptococcal* bacteria [199]. In Protein A/G-based methods, a cell mixture is incubated with a receptor-specific antibody and passed through a Protein A/G-linked adsorbent [200–205], where the antibody-labeled cells are selectively retained (Fig. 5). As the binding to Protein A/G is less impacted by steric hindrance than binding to immobilized antibodies directly, this variant of immunoaffinity cell chromatography is more efficient, and has been demonstrated in different formats, such as rosetting [206,207] and solid-phase chromatography [201,208].

4.4. Protein and synthetic antigens

Antigens represent a broad class of ligands ranging from proteins to small synthetic molecules [93,171,209–211]. The use of antigenic ligands for purifying white cells has been pioneered by Wigzell *et al.*, who isolated immunized mouse lymph node cells using glass and plastic beads functionalized with human serum albumin, bovine serum albumin, and ovalbumin with yields between

60–95%, but poor enrichment (2.5-fold) [212]. Later work on lymphocytes has utilized enzyme-substrate interactions to isolate lymphocytes raised against enzyme antigens [213]. To purify enzyme-binding lymphocytes, Deluca *et al.* contacted white cells with the antigen enzyme and then exposed the solution to beads decorated with the enzyme’s substrate to specifically capture enzyme-bound lymphocytes [210].

Synthetic antigens represent the first use of synthetic ligands for cell purification [214–217]. Truffa-Bachi *et al.* utilized haptens as antigens to stimulate an immune response, and subsequently as immobilized ligands to isolate white cells with anti-hapten activity [214,215]. This method addresses two main difficulties encountered in affinity-based capture, namely (i) non-specific binding of non-target cells and (ii) detaching cells from the adsorbent without impacting their viability. In this context, Haas *et al.* utilized a gelatin matrix containing dinitrophenyl as a ligand for adsorbing mouse spleen cells, demonstrating that 30-fold enrichment and high viability could be achieved by melting the gelatin, providing for a gentle elution strategy [217].

4.5. Lectins

Lectins recognize specific carbohydrate sequences on glycoprotein cell surface markers and have been widely utilized for cell fractionation (Fig. 6) [218]. Herz *et al.* have used soybean agglutinin as a ligand to isolate T lymphocytes from peripheral blood for use in the prevention of graft vs. host disease in bone marrow transplants [219]. Hellström *et al.* have shown how helix pomatia A hemagglutinin can bind T cells treated with neuraminidase by targeting surface carbohydrates [220]; because only a small fraction of B cells interact with helix pomatia hemagglutinin, this method represents an efficient strategy to separate T cells from B cells [221]. This work shows how lectins enable highly specific cell fractionation as they target post-translational modifications; helix pomatia hemagglutinin, in fact, is selective for human T cells over many B cells since T cells express proteins with unique post-translational modifications [222]. Another major advantage of lectins is that cell elution can be triggered by mono- and disaccharides, which are harmless to cells [171]. In one instance, though, the elution of mouse thymocytes from concanavalin A was accomplished by cleaving the mercury-sulfur bond conjugating the lectin ligands from the chromatographic substrate using a short thiol, affording quantitative recovery and high cell viability [223].

5. Formats of affinity-based cell separation

The principles of affinity purification have been applied in different ways for cell capture, depending on the source fluids and the required throughput [26,100,140,150]. Cell-binding ligands have been immobilized onto solid substrates (chromatographic-like




Fig. 5. Protein A-based cell affinity chromatography. (A) Mixing the target cell and other cells with target-specific antibodies; (B) Incubating antibody bound cell mixture with a Protein A functionalized surface. (C) Removing the unbound cells by washing; (D) Eluting the target cell.




Fig. 6. Lectin-based cell affinity chromatography. (A) Contacting a mixture of cells with the lectin substrate; (B) Removing the unbound cells by washing; (C) Eluting the target cells using a mixture of sugars.

methods) [128] or polymer carriers (pseudo-/non-chromatographic method) [224] as well as magnetic particles (MACS) [225] and fluorescent markers (FACS) [226] that enable separation by an electromagnetic field. More recently, affinity ligands have been displayed on the channels of microfluidic devices. This latest frontier of cell separation offers higher resolution and holds great promise to expedite the clinical implementation of cellular therapies relying on rare cell types.

5.1. Rosetting

Rosetting was the first isolation method to combine affinity with traditional density-gradient separation methods [150,227–229]. In this technique, antigen-specific cells are incubated with antigen-coated erythrocytes, with which they form aggregates, called “rosettes”, that are separated from non-rosetted cells by gradient centrifugation (Fig. 7) [230]. Rosetting was first utilized

to separate two mouse immune cell populations using sheep red blood cells [231]. Further work demonstrated that greater quantities and purities of rosette-forming antigen-specific cells could be obtained through avidin-biotin affinity [207], gradient density centrifugation [18], and in combination with magnetic fields [232]. Rosetting is now routinely employed for purifying B and T lymphocytes and stem cells [233], with commercial products such as the RosetteSep™ kit from StemCell, which offer good recovery and purity.

5.2. Chromatography

Besides recovery and purity, other parameters, such as scalability and capacity, are critical to extend cell separation processes to clinical and commercial applications [128,234]. In this context, cell affinity chromatography (CAC) shows great promise as a scalable technology [235], given its successful use in industrial pro-




Fig. 7. Cell rosetting technique. (A) Contacting the target cell and other cells with bi-specific (target cell and red blood cells) ligands resulting in (B) the formation of a complex; (C) Incubating the tagged target cells with red blood cells; (D) Procedure of cell purification by rosetting and density gradient centrifugation.

tein purification [236,237]. In CAC, cells are injected into a column packed with a porous material functionalized with affinity ligands. Target cells are retained by affinity on the chromatographic medium, while other components flow through (Fig. 4). While similar to traditional protein chromatography, CAC faces unique challenges, due to the major differences between cells and proteins: cells are large, sensitive to shear stress [204], and possess a low diffusivity, which results in the need for convective transport to achieve sufficient interaction with the affinity surface [238–240]. Most importantly, high binding avidity requires harsh elution conditions to elute the cells from the chromatographic substrate [204,241–243]. These challenges have highlighted the need for matrices that are tailored for chromatographic cell separations.

Computational modeling has been utilized to simulate cell interactions with affinity surfaces and guide the design of CAC substrates. Hammer *et al.* modeled the receptor-mediated adhesion of cells to ligand-decorated surfaces [238] and found that adhesion mainly depends on (i) the cell receptor-ligand interaction, such as the bond formation rate (k_{on}) and strength (K_D), and (ii) the fluid mechanical force, receptor mobility, and contact area [244–250]. The model predicts two regimes governing CAC, *i.e.* a rate-controlled high-affinity regime and a low-affinity regime. Additional studies have expanded on CAC modeling [251] by implementing advanced analytical [252–254] and numerical [244,255–257] approaches, understanding the effect of contact time and presence of inhibitors on cell adhesion [258], evaluating the effect of cell deformability on adhesion to surfaces [259,260], and observing cell binding in microfluidic channels [261,262]. A model based on “cell rolling” behavior, inspired by leukocytes rolling against blood vessel walls [263,264], was designed to increase the likelihood of ligand-receptor interactions [143,145,256,265–268], reduce residence times, and secure the binding of cells with low surface marker density.

In place of traditional chromatographic substrates, alternatives such as fluidized bed CAC, cryogel CAC, and microfluidic CAC, have been proposed [234].

5.3. Fluidized Beds

Fluidized bed, or expanded-bed, affinity adsorption is frequently used to harvest from crude feedstocks [269]. A fluidized bed is comprised of porous particles coated with cell-binding affinity ligands that are agitated by an upward flow of fluid containing the target cells (Fig. 8). The advantages of this technique over traditional CAC are (i) improved mass transfer and (ii) large inter-particle volume, and (iii) high surface area [221,270–272]. In one study, perfluorocarbon-based beads functionalized with lectin Concanavalin A were utilized to capture *Saccharomyces cerevisiae* cells [271,273]. The rapid adsorption kinetics enabled the capture of up to $6.8 \cdot 10^9$ cells/mL, although elution was hindered by the “avidity” effect; to facilitate elution, ion-exchange groups were used in lieu of Concanavalin A [270,271]. Fluidized bed separation was also utilized to isolate monocytes labeled with biotinylated antibodies from human peripheral blood using streptavidin beads [272]; cells were eluted using mechanical shear to a purity of 90%, yield of 77%, and viability of greater than 65%. While promising, fluidized beds suffer from limitations such as shear stress on cells, the need for large columns, long equilibration times, non-specific capture by the adsorbent base material, limited flow velocities, disengagement of absorbed cells from ligands [270], and fouling of the beads [274].

5.4. Cryogels

Another alternative to traditional CAC is represented by monolithic cryogels [128,234,275,276]. Cryogel matrices are prepared by gelation or polymerization at sub-zero temperatures to create a continuous macroporous structure that enables cell suspensions to flow through [275] (Fig. 9). While initially designed for the separation of proteins [277], oligonucleotides [278], and plasmids [279], cryogels have been shown to be ideal for the purification of viruses [280], cell organelles [281], and whole cells [234] owing to their (i) uniform and highly interconnected pores [128,234], (ii) high channel width ($>30 \mu\text{m}$) that provides for efficient transport of cells between 2 and $15 \mu\text{m}$ [128,282], (iii) efficient ligand




Fig. 8. Cell purification by expanded bed chromatography. (A) Filling the column with beads; (B) Expanding the beads; (C) Loading the cell mixture; (D) Compacting and washing the beads; (E) Eluting the target cells.




Fig. 9. Process of cryogel production.

conjugation [204,205,283], and (iv) high elasticity and hydrophilicity, which is particularly suited for mammalian cells [234,284]. Finally, cryogels are attractive for large scale manufacturing as they exhibit high storage stability and have an extended life cycle [205,285]. The two main approaches for cell capture using cryogels are mechanical entrapment in the cryogel matrix and ligand-mediated binding [140,275,286,287]. Ligands are conjugated to the cryogel either during or after cryogenic pore formation [281,288]. A wide array of ligand formats [234,285,288] including antibodies [204,205,247,289,290], proteins [128,204,205,286,291], lectins, and synthetic ligands [290,292–294] have been incorporated into cryogels for the separation of lymphocyte cells [128,204,285], myeloid cells [276,295], microbial cells like *Staphylococcus aureus* [290], *Escherichia coli* [286,291,296], *Bacillus halodurans* [297], and yeast cells [286,291]. Elution from cryogels can be achieved by traditional methods, as well as by elastic deformation and thermally-induced shrinkage of the matrix to ensure viability of the recovered cell product [291].

6. Pseudo-chromatographic systems

6.1. Gel Affinity Separation

Among polymer-based media, gels are particularly attractive as single-use adsorbents for cell purification, as they can be disintegrated thermally or enzymatically to release viable cells [298–305]. Haas and Layton developed antigen-coated gelatin layers to separate spleen cells with a 30-fold enrichment [217]; the bound lymphocytes were recovered by melting the gelatin. Because cell recovery could only be performed below gelatin's melting tem-

perature, Maoz *et al.* modified this process by including matrix-specific enzymes (*i.e.*, collagenase) [303]; less than 5% of non-specific cells bound the gel, and non-adherent cells had significantly lower cytotoxicity than the bound cells, indicating that this method can specifically isolate functional T cells. Bröcker *et al.* developed antigen-functionalized gelatin for purifying T cells with up to 100-fold enrichment and purity of 80–90% [304]. Similarly, Webb *et al.* used an anti-mouse IgG for the selective capture of B cells [302]; on average 250 cells/mm² attached to the immobilized antibody and the B cells had a minimum viability of 60%.

6.2. Fiber-based affinity separations

Arrays of parallel hollow fibers have gained popularity as substrates for affinity purification of cells [306–313]. Fibers introduce a new component in cell adhesion, represented by the fiber's cross-section geometry and flexibility [309,312]. Fiber-based adsorbents are also attractive as they can be regenerated by washing at high shear [308,312] and can be manufactured affordably at large-scale. The first use of fibers for cell isolation was published by Edelman *et al.* [306], who described the isolation of spleen cells from mice, immunized against Dnp38-bovine IgG, using nylon fibers coated with Dnp38-BSA, tosyl₃₀-BSA, and BSA antigens. The cells were detached mechanically, chemically, or competitively by incubation with inhibitors. While the eluted cells were up to 90% viable, significant non-specific binding occurred, which limited purity to 63–88%. To increase specificity, several authors have coupled antibodies and antigens to the luminal surface of cellulose hollow fiber modules. Pope *et al.* covalently attached goat anti-mouse antibodies to cellulose fibers to capture CD4⁺ lymphocytes, resulting in

63–99.9% depletion of the CD4⁺ cells from the starting population [314]. Similarly, Nordon *et al.* covalently coupled an anti-CD34 antibody directly to the luminal surface of their system's fibers to enrich CD34⁺ cells from mononuclear cells at 94% purity and 61% yield [307]. Other groups have developed fusion proteins comprising an antibody-binding domain and a fiber-binding domain for mediating the adhesion of antibody-labeled cells onto the fibers. Specifically, Craig *et al.* developed a fusion protein ("protein LG") that captured more than 90% of the antibody-labeled CD34⁺ cells onto a cellulose fiber module [311]. The use of these chimeric proteins helps overcome problems associated with ligand conjugation to hollow fibers such as low yield, random orientation, and structural alterations or degradation caused by the conjugation chemistry [311]. Hollow fiber systems enable the implementation of unconventional elution techniques. For example, bound cells can be fractionated into populations with varying binding strength by adjusting the flow rate (shear elution) [312]. Bound cells can also be eluted if labile links (e.g., a disulfide bond) are included between the ligands and fibers.

6.3. Affinity Membranes

Membranes are suitable substrates for affinity cell separations, as the balance between trans-membrane flux and fluid velocity parallel to the surface can be easily controlled to optimize adsorption and elution [138,315]. Additionally, the pore size of membranes and surface shear can be varied to minimize concentration polarization and fouling, which is advantageous when processing high-density cell suspensions. In an early example, Mandrusov *et al.* used a cellophane dialysis membrane functionalized with goat anti-mouse immunoglobulin to purify mouse B-lymphocytes [316]: cells were eluted with a low pH buffer by trans-membrane diffusion, while a shear-producing flow was applied to promote detachment of the cells from the membrane and neutralization of the acidic environment. Feeding the elution buffer on the membrane side opposite to the bound cells afforded a 100% yield and 60% viability, indicating that a trans-membrane pH gradient is needed to elute cells effectively without decreasing cell viability.

Affinity membranes enable cell separation processes that employ bubble-induced cell detachment [317]. This technique is attractive as cells can be removed from adsorption surfaces without excessive dilution. Wang *et al.* utilized this method with tubular capillaries coated with antibodies to purify specific blood cell populations [127], obtaining 85.7% yield, 97.6% purity, and 85.8% viability of CD4⁺ cells isolated from blood samples. Specifically, > 90% of cells detached by bubble-induced elution, whereas compression and flow-induced elution resulted in 40–80% and 10–40% of cell detachment, respectively [317].

Thermo-responsive polymers have also been integrated in membranes to improve elution. Specifically, a poly(N-isopropylacrylamide)-grafted polypropylene (PNIPAAm-g-PP) membrane functionalized with monoclonal antibody ligands was developed for purifying CD80⁺ cells [318]. PNIPAAm displays a thermo-responsive phase transition at 32°C, where it switches from a hydrophilic to a hydrophobic state. At 37°C, antibody ligands adhere to the PNIPAAm-g-PP membranes by hydrophobic interaction, enabling the affinity capture of CD80⁺ cells; at 4°C, the IgG ligands detach from the PNIPAAm coating, thereby releasing the cells. The recovered cells were enriched from a 1:1 cell suspension to 72%, proving to be the first case of affinity-based capture of cells where temperature is used for cell elution. In a similar work, anti-CD34 antibodies were adsorbed onto a PNIPAAm-g-PP membrane and utilized to enrich CD34⁺ cells. The CD34⁺ cell concentration was increased from 50% in the feedstock to 85% in the eluate, and 95% of the recovered cells were viable [319].

7. Non-chromatographic affinity purification methods

A variety of non-chromatographic techniques have been developed, such as two-phase separations, magnetic-activated cell sorting (MACS) and fluorescence-activated cell sorting (FACS) [148]. Two-phase separations employ polymeric materials often labeled with affinity ligands to drive the selective migration of cells into an aqueous phase (Fig. 10). In MACS and FACS, the target cells are tagged with labeled affinity ligands that enable separation; magnetic labels are used in MACS (Fig. 11), while fluorescent labels are used in FACS (Fig. 12). While MACS and two-phase separations isolate cells into bulk groups, FACS is unique in its ability to analyze and sort single cells, allowing for more precise cell separation.

7.1. Affinity two-phase partitioning

Affinity two-phase partitioning is a powerful preparative method for cells, cell membranes and organelles, and viruses [140,320–329]. Aqueous two-phase systems (ATPS) form when two polymers added to a water solution produce two non-miscible liquid layers, across which other components in solution migrate based on their differential affinity towards the polymers (Fig. 10). To improve the selectivity of cell migration, affinity ligands such as lectins, antibodies, and receptor-specific molecules have been conjugated to the phase-forming polymers [330,331]. Polyethylene glycol (PEG) and dextran are the most commonly utilized polymers for ATPS, with PEG being used as the ligand carrier and the dextran-rich phase acting as the receptacle for the bulk contaminants [325,332–334]. Monoclonal antibodies coupled to PEG have been utilized for separating human red blood cells from sheep and rabbit blood cells, resulting in up to 92% partitioning of the human red blood cells to the top phase [321,335,336]. Antibody-PEG conjugates have also been used to purify hybridoma 16-3F cells from their parental NS-1 cell line, resulting in 24% recovery and 80% purity [332].

Two-phase affinity partitioning has flourished with the introduction of stimuli-responsive polymers. Kumar *et al.* have utilized PNIPAM decorated with antibody ligands to separate CD34⁺ human acute myeloid leukemia KG-1 cells from Jurkat cells (immortalized human T lymphocytes) [337]. While more than 80% of the KG-1 cells were partitioned to the top phase, a small contamination of Jurkat cells was observed; however, incomplete recovery of the conjugates lowered the yield of KG-1 cells to 75% during subsequent use. In addition to antibodies, cell separation by two-phase partitioning has also been demonstrated with other ligands, such as transferrin [323], synthetic dyes [338–342], and immobilized metals [333,343].

Owing to its biocompatibility, mild operating conditions, and scalability, ATPS is regarded as a high-potential technology for the recovery of cell targets for which the minimization of mechanical stimuli is critical (e.g., stem cells and neurons) [327,328]. Sousa *et al.* used PEG800-dextran functionalized with anti-CD34 antibodies to separate and recover CD34⁺ stem cells from umbilical cord blood [325]. The CD34⁺ cells were enriched from a starting population of ~ 0.2% CD34⁺ cells to ~ 42% in the final population, and recovered with 81–95% yield; in contrast, with PEG alone, a cell enrichment of 13% and 2.3% recovery was achieved. Using a three-polymer (PEG, ficoll, dextran) system and an anti-CD133 antibody, González-González *et al.* recovered CD133⁺ stem cells from umbilical cord blood with a final recovery of 62% and 98% viability [328].

A significant limitation of two-phase separations is the recurring presence of impurities in the top (product) phase. Accordingly, separations using ATPS generally result in lower purity than what is achieved using chromatographic technologies. Further work to improve ATPS separations, especially by increasing the partition preference of antibodies to a top clean phase, is considered a




Fig. 10. Cell purification by affinity-based aqueous two-phase partition. (A) Suspending the cell mixture; (B) Adding the affinity-polymer forming the second phase; (C) Mixing the two phases; (D) Allowing the two phases to separate and recovering the target cells in the top affinity phase.




Fig. 11. Cell purification by MACS. (A) Contacting the cell mixture with ligand-functionalized magnetic beads; (B) Suspending the magnetic beads in the cell mixture; (C) Applying a magnetic field to isolate the magnetized target cells and remove all unbound cells; (D) Resuspend and wash the magnetized target cells; (E) Elute the target cells from the magnetic beads.

worthwhile effort to achieve a truly scalable process for cell separation.

7.2. Magnetic-activated cell sorting (MACS)

MACS is a relatively recent cell separation technology that employs affinity ligands conjugated to magnetic particles comprising an iron core coated by a hydrophilic shell to reduce non-specific binding (Fig. 11) [344]. Upon incubating ligand-coated particles

with a cell mixture, a magnetic field is applied to separate the target cells bound to the magnetic particles from the unbound cells [345]. Pioneered by Zborowski and co-workers [142,346–350], MACS is now recognized for its speed of separation, with rates in the range of $\sim 10^{11}$ cells/hour [100]. Recent developments enable simultaneous separation of multiple cell types using magnetic field gradients [348,351] or in combination with microfluidic devices [352,353]. The predominant MACS format is antibody-based, where target cells are either directly bound onto antibody-coated




Fig. 12. Cell purification by FACS.

beads [225,347], or are labeled in solution with a primary antibody and subsequently captured onto beads coated with a secondary antibody [354,355].

Ligand immobilization techniques are highly dependent on the nature of the ligand. Methods for antibody immobilization to magnetic particles include covalent binding [356,357], streptavidin-mediated immobilization (specific for biotinylated antibodies) [358,359], Protein A-/G-mediated immobilization [360], conjugation to boronic acid or hydrazinyl groups [360,361], and oligo-dT coating [362]. Besides antibodies [225,345,363–365], other affinity ligands have been successfully utilized in MACS [366–375]. Herr *et al.* utilized DNA aptamers to capture acute leukemia cells from complex mixtures with a 40% recovery [371]. Magnetic nanoparticles coated with bis-Zn-DPA, a synthetic ligand that binds Gram-positive and Gram-negative bacteria, have been utilized for separating *Escherichia coli* from blood with complete bacterial clearance in two separation cycles [375]. This work has also demonstrated that nanoparticles outperform micrometer-scale particles in terms of binding capacity and kinetics, and separation output.

The increasing relevance of immunomagnetic separation technology is demonstrated by the recent FDA approval of the CellSearch system, which can isolate circulating tumor cells using an epithelial cell-adhesion molecule (EpCAM) antibody [376–378].

7.3. Fluorescent-Activated Cell Sorting (FACS)

In FACS, fluorescently-tagged ligands are utilized to individually sort cells using fluorescence and light scattering [379–381].

When injected into the sorter, the stream of cells tagged with fluorescent ligands is broken into droplets that contain a single cell; each droplet passes through an illumination detection zone, and a charge is placed onto any cell that meets the separation criteria. As the charged droplets fall through electrostatic deflecting plates, they are sorted into different containers based on their charge (Fig. 12). FACS has been extensively utilized for sorting therapeutic cell products, especially stem cells [29,31,382–384] and blood cells [385,386]. FACS has gained popularity as it provides highly pure (>95%) cell populations and can sort at the single cell level due to the high sensitivity of fluorescence detection [100,387]. FACS also allows population-averaged single cell data, as it can be used to efficiently perform high throughput cell sorting and counting [387]. Recent advances in fluorescent dyes and laser detectors allow researchers to simultaneously track multiple cell parameters [388,389]. On the other hand, FACS requires the use of expensive equipment and suffers from limited throughput ($\sim 10^7$ cells/hour) and long processing times (3–6 hours), which prevents its use in large scale manufacturing of therapeutic cells [380].

Elements of MACS and FACS sorting can be combined in a method known as “ratcheting cytometry” to perform multicomponent purifications of specific subpopulations [390]. This method is frequently used for continuous and quantitative purification of T cell subsets for cell therapy manufacturing. Specifically, T cells from apheresis or peripheral blood mononuclear cell samples are magnetically labeled using magnetic particles featuring different iron oxide content and size as well as antibody functionalizations. As magnetic particles travel differently within the sorting cartridge based on their magnetization and size, cells specifically bound to

a magnetic particle population can be isolated from other cells in the mixture [390]. Ratcheting cytometry also enables sorting cells based on differential levels of antigen, as this determines the number of magnetic particles bound to a cell. This method has been used to simultaneously isolate CD4⁺ and CD8⁺ T cells from a sample via labeling with antigen-specific magnetic particles [391].

8. Emerging Trends

Cell purification technology is rapidly evolving, owing to the introduction of target-specific biorecognition moieties for capture (i.e., biological and synthetic ligands) and emerging isolation formats (e.g., microfluidic devices).

8.1. Microfluidic devices for cell separation

The latest frontier of CAC is represented by microfluidic devices that comprise sub-millimeter channels coated with affinity ligands (M-CAC) [129,131,159,392–396]. The high surface-area-to-volume ratio of microfluidic channels, enhanced by micro-fabricated structures with complex geometry, has enabled the capture of cells at extremely low concentrations by M-CACs [261,392,397–399]. M-CAC systems have been utilized to separate T- and B-lymphocytes at high purity (> 97%) from mixed suspensions [127,175,400]. To ensure binding specificity, the channels are often grafted with hydrophilic polymer brushes (e.g., PEG) or coated with hydrogels (e.g., alginate) functionalized with antibody ligands [401,402]. Chang *et al.* have developed a M-CAC system coated with E-selectin IgG molecules to separate HL-60 and U-937 myeloid cells with purity greater than 70% and 200-fold enrichment [262]. M-CAC also enables the sorting and capture of multiple cell types from a complex mixture. Li *et al.* incorporated a pneumatic-actuated control layer into an affinity separation layer to create different antibody-coated regions within the same channel [129]. Ramos cells were flown through anti-CD19- and anti-CD71- coated regions, with the anti-CD19 region having a capture density 2.44-fold higher than the anti-CD71 region. The authors also coated a second channel with two different antibodies targeting either Ramos or HuT 78 cells, allowing specific retention of the cells in their complementary region at greater than 90% purity. Lastly, a four-region antibody-coated device was developed for the simultaneous capture of three different cell lines in a single channel, thereby enabling multiplexed cell sorting.

Microfluidic devices coated with antibodies against specific cell markers have gathered considerable interest as tools for detecting rare tumor circulating cells (CTCs) [397,403–405]. Isolating CTCs from the bloodstream enables the detection, characterization, and monitoring of non-hematological cancers [406], but is made extremely challenging by their low concentration (1–100 CTCs per mL of blood [82,376–378, 407,408]). Researchers have shown that microfluidic devices (CTC-Chip) containing an array of microposts functionalized with epithelial cell adhesion molecules (EpCAM) can capture CTCs [397]. Many attributes of the device have been explored to enhance CTC enrichment. Gleghorn *et al.* described how the geometry of the microposts can enhance CTC enrichment [398]. CTC-ligand binding has also been improved by introducing a high-throughput microfluidic device called “HB-Chip”, which mixes the blood cells by generating micro-vortices that increase the interactions between the target CTCs and the antibody-coated channels [406]. To increase binding sensitivity, Myung *et al.* developed high-avidity ligands by conjugating multiple EpCAM ligands to dendimers [409]. The combination of multivalent binding and cell rolling in the channels mediated by E-selectin granted high sensitivity and specificity towards CTCs. This work has led to a device, commercialized by Biocept, which employs streptavidin-coated microposts to capture CTCs tagged with biotinylated an-

tibodies, followed by fluorescent microscopy-based detection and *in situ* cytogenetic interrogation [399,410]. Another approach for the isolation of CTCs is represented by negative enrichment (or negative selection) using microfluidic technologies [411], which takes advantage of the physical and biochemical properties of cells [412]. Unlike hematopoietic cells, which display the cell surface markers CD15 (granulocytes), CD66b (granulocytes) and CD45 (leukocytes), CTCs are CD15/66b/45-negative. Accordingly, negative enrichment technologies feature microfluidic channels, nanoparticles, and micro-scale adsorbents functionalized with anti-CD15, anti-CD66b and, most commonly, anti-CD45 antibodies [155–157]. Affinity-based negative selection alone, however, is often not sufficient to achieve the desired enrichment factor, and must be complemented by size exclusion-based or fluid dynamic-based separation techniques [157,158,160,413,414].

Lastly, emerging technologies for droplet-based single cell analyses are flooding the contemporary literature landscape. While there is significant focus on droplet barcoding for single cell sequencing and transcriptomics [415–418], some efforts are aimed at employing droplet-based technologies for human cell isolation, sorting, and studying biomolecular interactions [419–425]. An in-depth review of droplet-based cell analyses was recently provided by Huck *et al.* [426]. Briefly, the formation of water-in-oil plug flow in microfluidics can generate picoliter-sized droplets for carrying cells or other biomolecular residents, and these droplets can be generated in a highly repetitive and chemically-defined manner [427–430]. When employed for cell isolation and sorting, the physico-chemical properties of the droplet can be tuned to promote interaction with specific surface features of the microfluidic device, resulting in droplet isolation and sorting [431–435]; for example, the interfacial tension of the droplet can be made sensitive to pH causing the droplets to interact with the microfluidic channel's surface [422]. The physico-chemical properties of the resident cell can also be made responsive, so that the droplet can be sorted via imaging and fluorescence-activated techniques [436–440].

In regard to using these techniques for studying affinity-based chemistries, droplet microfluidics have been employed to screen drug and antibody binding by generating sub-nanoliter reactors [441–444]. In one example, hybridoma cells secreting antibodies were individually co-encapsulated with a target cell in nanodroplets to select hybridoma clones expressing antibodies featuring affinity for the target cell [440]. While there have been limited studies of strictly affinity-based sorting via droplet microfluidics, based on the aforementioned examples, there is an emerging lane of study for using droplet microfluidics for therapeutic antibody discovery, especially since the single-cell droplet approach is amenable to use with primary human plasma cells, which secrete antibodies.

8.2. Synthetic Ligands

A significant barrier to improving the affordability of cell products is represented by the cost of biological ligands [133]. While highly selective, proteins and antibodies are biochemically labile [445], and a complex engineering process is required to discover viable ligands [446]. Further, they are generally characterized by high binding strength, which can trigger undesired intracellular signaling cascades upon binding and even cell death [447–449]. To overcome these limitations, synthetic ligands have been proposed to maintain targeted affinity while lowering binding strength to facilitate cell elution. In addition, synthetic ligands are biochemically stable and can be synthesized affordably at large scale.

Hormones are the first small molecules to ever be utilized as affinity ligands [450]. In particular, histamine [451,452], catecholamines [453], and prostaglandins [454,455] coupled to Sepharose beads have been used to separate 19S and 7S plaque-

forming cells from the total spleen leukocyte population. The hormone-based adsorbents were able to capture 56% and 84% of the 19S and 7S plaque-forming cells respectively. Similarly, glycans (e.g., mannose) immobilized on Dowex resins have been utilized to separate *E. coli* K12 and *Campylobacter jejuni* NCTC 11168 cells with high yield (94–96%) and selectivity [456].

Recent advances in selection technology have spurred the use of synthetic ligands with engineered affinity and selectivity for any target cell [133,457–459]. Aptamers and peptides represent the main classes of synthetic ligands [449,460–470]. Aptamers consist of single-stranded DNA or RNA molecules and have seen rising popularity in cell purification [469]. The development of these ligands is supported by a high-throughput screening method known as “systematic evolution of ligands by exponential enrichment” (SELEX) [464,471–474]. Xu *et al.* have selectively captured three leukemia cell lines (CCL-119, Ramos cells, and Toledo cells) using a microfluidic device coated with cell line-specific aptamers, with up to 136-fold enrichment [475]. Aptamers have also been demonstrated as cell capture ligands in more traditional pseudo-chromatography applications, as described by Zhang *et al.*, where aptamers coupled to a hydrogel bound and eluted target cells with a resulting viability of ~ 99% [476]. Aptamers have also been successfully used in MACS applications [371,372,475,477–480], microfluidic devices, and hydrogels, with reported capture efficiencies and cell purities at > 80% [131,403,481–483]. These case studies showcase the value of aptamers as cell capturing ligands. Nonetheless, some improvements are still needed, such as increasing binding selectivity to improve capture [484], tuning the binding strength to facilitate cell elution [485], and addressing safety concerns by implementing rigorous tests of biocompatibility [486].

Peptides have also emerged as robust and cost-effective alternatives to protein ligands [133]. Over the past two decades a number of selection techniques have been developed, ranging from the screening of biological and synthetic libraries in liquid or solid phase to *in silico* approaches, such as computational design and machine learning. This has resulted in a myriad of peptides targeting analytical and medically relevant target cells. Veleva *et al.* identified an angiogenic tumor-binding peptide via *in vitro* enrichment of a peptide library against peripheral blood outgrown endothelial cells followed by *in vivo* screening of the enriched library to identify tumor-binding peptides [487]. Similarly, Oyama and coworkers identified peptides from a phage library to bind human lung cancer cell lines and noted that the selected peptides were specific towards the target cancer cells without negative selection [461,466]. In 2008, Choi *et al.* identified a Raji cell-targeting peptide as a model for Burkitt lymphoma cells with seemingly high specificity for these cells as determined by lack of binding to normal, non-cancerous B cells, peripheral blood cells, or other leukemia cells [488]. Wang *et al.* also utilized phage display to identify affinity peptides for imaging detection of human colorectal cancer cells (Caco-2); the specificity of the peptide was confirmed using negative-control cell lines HEK293, SGC-7901, and SMMC-7721 [489]. Peptide ligands have also been employed in a number of cell adhesion applications, which are of primary interest for cell separations. De *et al.* demonstrated the use of peptides in pathogen removal applications by isolating pancreatic beta-cells infected by *Mycoplasma arginii* from healthy cells, showcasing a 10-fold reduction in the number of infected cells [490]. Success in separating different phenotypes of primary cells has also been shown in multiple cases by microcontact printing of tetrameric peptides in microfluidic devices. These have been used for the separation of osteoblasts from fibroblasts by Hasenbein and coworkers [491], or the fractionation and characterization of different human cell phenotypes by Murthy and coworkers [492–494]. Peptide ligands have been discovered for a number of cell surface markers that identify analytically or therapeutically relevant cells, including CD34

[495], CD133 [496,497], CD38 [498], VCAM1 [499–502], and FLT3 [503,504].

Large peptides, developed from non-antibody scaffolds, also represent a viable alternative for cell separation purposes. Our group has identified the first non-antibody binders for CD117 by screening a yeast-display scaffold library against magnetized yeast cells expressing the extracellular domain of CD117 [505]. Two nanobody mutants were identified with good affinity (*i.e.*, 131 and 204 nM) for CD117. While binding of these mutants for CD117 was only confirmed for yeast displayed CD117, a combination of these ligands would likely enable the purification of phenotypically pure cells such as endothelial stem and progenitor cells (ESCs, EPCs), and hematopoietic stem and progenitor cells (HSCs, HPCs) [506–517]. Additionally, the mid-nanomolar affinities of the nanobody ligands promote gentler elution compared to antibody ligands.

Peptide ligands can also be engineered to enable the control of cell binding and release upon exposure of biocompatible stimuli. To this end, stimuli-responsive monomers can be incorporated into the amino acid sequence, allowing the peptide to reversibly switch between a binding and a non-binding mode upon cooling, or exposure to light or a magnetic field (Fig. 13). Our group, for example, has developed VCAM1-binding azobenzene-cyclized peptides for the light-controlled labeling of endothelial progenitor cells [518]. Upon exposure to light, the ligands undergo a remarkable ~ 1300-fold variation in binding strength, which enables selective and stable light-controlled labeling of cells. Notably, modified azobenzene linkers have been engineered to photo-switch in different wavelength windows, namely red, green, and blue (RGB) light [519–524]. Therefore, a combination of peptide ligands targeting different cell markers, whose binding/release is triggered at different wavelengths, could be used to produce and dynamically modify patterns of cells on solid substrates by exposure to sequences of red, green, or blue photo-patterns, for example using liquid crystal display light-emitting diodes (LCD-LED) arrays.

9. Conclusions

Cell separation technologies have progressed steadily to meet the demands for basic research, diagnostic, and therapeutic applications, resulting in cell isolation methods that are more efficient, scalable, and dependable. Affinity-based approaches are now the most utilized, owing to their ability to achieve high purity. A wide variety of affinity-based approaches are available, ranging from traditional chromatographic to pseudo- and non-chromatographic systems. Each system has advantages and disadvantages, as outlined in this work, which must be carefully considered when choosing a cell separation method. Microfluidic technologies represent the next frontier of cell manufacturing as they offer the capacity to perform multiple functions (mixing, counting, lysis, single cell analysis, etc.) in a single device. Advances in parallelization and scale-up hold great promise to overcome the low throughput of current devices and enable processing of large sample volumes. Further, the ability to integrate post-sorting molecular, cellular, and functional characterization furthers the appeal of using microfluidic devices for cell separation.

On the biorecognition front, affinity-based separations are shifting from protein and antibody ligands towards synthetic ligands. Biological ligands, in fact, while highly specific, are limited by their high cost and exceedingly strong binding. Synthetic ligands, on the other hand, can be synthesized affordably, at large scale, and with no batch-to-batch variability. The need to develop gentle cell elution conditions has stimulated the development of stimuli-responsive ligands, such as photo-switchable peptides, whose binding activity can be controlled by exposure to biocompatible stimuli. In this regard, further progress in the fields of *in vitro* and *in silico* selection methods is needed to expand the portfolio of




Fig. 13. Cell purification using stimuli-responsive peptide ligands. (A) Reversible photo- or thermo-switching of an azobenzene-cyclized peptide; (B) Principle of cell capture and release using stimuli-controlled cyclic peptides.

peptides and aptamers with tailored binding and affinity for cell surface markers. Further studies – both experimental and modeling – are also needed to understand the relationship between affinity and multivalent binding as a function of surface marker expression, in order to optimize the balance between efficient cell capture and elution, ultimately enabling high recovery and bioactivity.

Currently, the major challenge for cell therapies and related clinical applications resides in achieving rapid, efficient, and affordable separation while minimizing costs and attaining the required purity, yield, and functionality of the cellular product. Membrane-based separations show exceptional potential in large-scale production, particularly in combination with cell-specific biorecognition moieties that ensure high recovery, purity, and bioactivity of the cell product. Owing to their high pore diameter and porosity, in fact, membranes enable the processing of large volume cell suspensions at high flow rates, thereby increasing throughput and minimizing processing time, which aids in maintaining the viability of the cell product. On the front of basic cellular research and personalized medicine, the continued identification of highly specific markers defining cell populations [525], combined with the advancements in integrating physical and affinity-based strategies in miniaturized devices, will be critical for the fruition of patient-specific cellular therapies.

Declaration of Competing Interest

None.

Acknowledgments

This work was partially funded by a grant from the [National Science Foundation](#) (CBET 1511227 and 1743404). KB kindly acknowledges support from an NSF Graduate Research Fellowship and a National Institute of Health Molecular Biotechnology Training Fellowship (NIH T32 GM008776).

References

- [1] D. Food, Administration, Guidance for industry: guidance for human somatic cell therapy and gene therapy, Fed Reg (1998) 36413.
- [2] D.G. Halme, D.A. Kessler, FDA regulation of stem-cell-based therapies, Mass Medical Soc (2006).
- [3] H. Food, Drug Administration, Eligibility determination for donors of human cells, tissues, and cellular and tissue-based products, Final rule, Federal register 69 (101) (2004) 29785.
- [4] E. Regulation, 1394/2007 on advanced therapy medicinal products and amending Directive 2001/83, EC and Regulation (EC) No (2004) 726.
- [5] B. George, Regulations and guidelines governing stem cell based products: clinical considerations, Perspectives in clinical research 2 (3) (2011) 94.
- [6] E. Ratcliffe, R.J. Thomas, D.J. Williams, Current understanding and challenges in bioprocessing of stem cell-based therapies for regenerative medicine, British medical bulletin (2011) ldr037.
- [7] S.F. Badylak, D. Taylor, K. Uygun, Whole-organ tissue engineering: decellularization and recellularization of three-dimensional matrix scaffolds, Annual review of biomedical engineering 13 (2011) 27–53.
- [8] B.M. Bijonowski, W.M. Miller, J.A. Wertheim, Bioreactor design for perfusion-based, highly vascularized organ regeneration, Current opinion in chemical engineering 2 (1) (2013) 32–40.
- [9] M.J. Robertson, J.L. Dries-Devlin, S.M. Kren, J.S. Burchfield, D.A. Taylor, Optimizing recellularization of whole decellularized heart extracellular matrix, PloS one 9 (2) (2014) e90406.
- [10] S.E. Gilpin, H.C. Ott, Using nature's platform to engineer bio-artificial lungs, Annals of the American Thoracic Society 12 (Supplement 1) (2015) S45–S49.

- [11] Q. Zhou, L. Li, J. Li, Stem cells with decellularized liver scaffolds in liver regeneration and their potential clinical applications, *Liver International* 35 (3) (2015) 687–694.
- [12] G. Bosman, I. Bartholomeus, A. De Man, P. Van Kalmthout, W. De Grip, Erythrocyte membrane characteristics indicate abnormal cellular aging in patients with Alzheimer's disease, *Neurobiology of aging* 12 (1) (1991) 13–18.
- [13] G.J. Nossal, Negative selection of lymphocytes, *cell* 76(2) (1994) 229–239.
- [14] H. von Boehmer, Positive selection of lymphocytes, *Cell* 76 (2) (1994) 219–228.
- [15] A. Rawstron, N. Villamor, M. Ritgen, S. Böttcher, P. Ghia, J. Zehnder, G. Lozan-ski, D. Colomer, C. Moreno, M. Geuna, International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia, *Leukemia* 21 (5) (2007) 956–964.
- [16] A. Ozcan, U. Demirci, Ultra wide-field lens-free monitoring of cells on-chip, *Lab on a Chip* 8 (1) (2008) 98–106.
- [17] T.M. Gorges, K. Pantel, Circulating tumor cells as therapy-related biomarkers in cancer patients, *Cancer Immunology, Immunotherapy* 62 (5) (2013) 931.
- [18] A.P. Kodituwakku, C. Jessup, H. Zola, D.M. Robertson, Isolation of antigen-specific B cells, *Immunology and cell biology* 81 (3) (2003) 163–170.
- [19] E.C. Butcher, Can cell systems biology rescue drug discovery? *Nature Reviews Drug Discovery* 4 (6) (2005) 461–467.
- [20] J. Folkman, Angiogenesis: an organizing principle for drug discovery? *Nature reviews Drug discovery* 6 (4) (2007) 273–286.
- [21] B.-B.S. Zhou, H. Zhang, M. Damelin, K.G. Geles, J.C. Grindley, P.B. Dirks, Tumour-initiating cells: challenges and opportunities for anticancer drug discovery, *Nature reviews Drug discovery* 8 (10) (2009) 806–823.
- [22] M. Grskovic, A. Javaherian, B. Strulovici, G.Q. Daley, Induced pluripotent stem cells—opportunities for disease modelling and drug discovery, *Nature reviews Drug discovery* 10 (12) (2011) 915–929.
- [23] A. Gee, A. Durett, Cell sorting for therapeutic applications—points to consider, *Cytotherapy* 4 (1) (2002) 91–92.
- [24] L.P. Shulman, Fetal cells in maternal blood, *Current women's health reports* 3 (1) (2003) 47–54.
- [25] X. Hu, P.H. Bessette, J. Qian, C.D. Meinhart, P.S. Daugherty, H.T. Soh, Marker-specific sorting of rare cells using dielectrophoresis, *Proceedings of the National Academy of Sciences of the United States of America* 102 (44) (2005) 15757–15761.
- [26] R.K. Kumar, A. Lykke, Cell separation: a review, *Pathology* 16 (1) (1984) 53–62.
- [27] S.F. Ibrahim, G. van den Engh, High-speed cell sorting: fundamentals and recent advances, *Current opinion in biotechnology* 14 (1) (2003) 5–12.
- [28] M. Kamiyama, A. Kumar, Development of separation technique for stem cells, *Cell Separation* (2007) 173–193.
- [29] M.M. Diogo, C.L. da Silva, J. Cabral, Separation technologies for stem cell bioprocessing, *Biotechnology and bioengineering* 109 (11) (2012) 2699–2709.
- [30] S. Burger, Current regulatory issues in cell and tissue therapy, *Cytotherapy* 5 (4) (2003) 289–298.
- [31] C.A. McIntyre, B.T. Flyg, T.C. Fong, Fluorescence-activated cell sorting for CGMP processing of therapeutic cells, *BioProcess International* 8 (6) (2010) 44–53.
- [32] R. Brandenberger, S. Burger, A. Campbell, T. Fong, E. Lapinskas, J.A. Rowley, Cell therapy bioprocessing, *BioProcess Int* 9 (Suppl 1) (2011) 30–37.
- [33] C.E. Goldring, P.A. Duffy, N. Benvenisty, P.W. Andrews, U. Ben-David, R. Eakins, N. French, N.A. Hanley, L. Kelly, N.R. Kitteringham, Assessing the safety of stem cell therapeutics, *Cell stem cell* 8 (6) (2011) 618–628.
- [34] Y. Jung, G. Bauer, J.A. Nolte, Concise review: induced pluripotent stem cell-derived mesenchymal stem cells: progress toward safe clinical products, *Stem cells* 30 (1) (2012) 42–47.
- [35] H. Okano, M. Nakamura, K. Yoshida, Y. Okada, O. Tsuji, S. Nori, E. Ikeda, S. Yamanaka, K. Miura, Steps toward safe cell therapy using induced pluripotent stem cells, *Circulation research* 112 (3) (2013) 523–533.
- [36] O. Adewumi, B. Aflatoonian, L. Ahrlund-Richter, M. Amit, P.W. Andrews, G. Beighton, P.A. Bello, N. Benvenisty, L.S. Berry, S. Bevan, Characterization of human embryonic stem cell lines by the International Stem Cell Initiative, *Nature biotechnology* 25 (7) (2007) 803–816.
- [37] V.F. Segers, R.T. Lee, Stem-cell therapy for cardiac disease, *Nature* 451 (7181) (2008) 937–942.
- [38] W.S. Bowen, Development and characterisation of affinity devices for cell detection and separation, © William Bowen, 2015.
- [39] G. Bosman, J. Werre, F. Willekens, V. Novotný, Erythrocyte ageing in vivo and in vitro: structural aspects and implications for transfusion, *Transfusion Medicine* 18 (6) (2008) 335–347.
- [40] Z. Taimeh, R.J. Koene, J. Furne, A. Singal, P.M. Eckman, M.D. Levitt, M.R. Pritzker, Erythrocyte aging as a mechanism of anemia and a biomarker of device thrombosis in continuous-flow left ventricular assist devices, *The Journal of Heart and Lung Transplantation* 36 (6) (2017) 625–632.
- [41] S. Dinkla, Erythrocyte aging and disease A tale of membranes and microparticles, *Ned Tijdschr Klin Chem Labgeneesk* 41 (3) (2016) 217–228.
- [42] L. De Franceschi, O. Olivieri, R. Corrocher, Erythrocyte aging in neurodegenerative disorders, *Cellular and molecular biology (Noisy-le-Grand, France)* 50 (2) (2004) 179–185.
- [43] S. Moir, A.S. Fauci, B cells in HIV infection and disease, *Nature Reviews Immunology* 9 (4) (2009) 235–245.
- [44] C.S. Hampe, B cells in autoimmune diseases, *Scientifica* 2012 (2012).
- [45] M.R. Edwards, P. Sultan, A.G. Del Arroyo, J. Whittle, S.N. Karmali, S.R. Moonesinghe, F.S. Haddad, M.G. Mythen, M. Singer, G.L. Ackland, Metabolic dysfunction in lymphocytes promotes postoperative morbidity, *Clinical Science* 129 (5) (2015) 423–437.
- [46] C.G. Lian, E.M. Bueno, S.R. Granter, A.C. Laga, A.P. Saavedra, W.M. Lin, J.S. Susa, Q. Zhan, A.K. Chandraker, S.G. Tullius, Biomarker evaluation of face transplant rejection: association of donor T cells with target cell injury, *Modern Pathology* 27 (6) (2014) 788–799.
- [47] A.M. Krensky, A. Weiss, G. Crabtree, M.M. Davis, P. Parham, T-lymphocyte-antigen interactions in transplant rejection, *New England Journal of Medicine* 322 (8) (1990) 510–517.
- [48] J. Finke, C. Schmoor, W.A. Bethge, H. Ottinger, M. Stelljes, L. Volin, D. Heim, H. Bertz, O. Grishina, G. Socie, Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial, *The Lancet Haematology* 4 (6) (2017) e293–e301.
- [49] S.J. Galli, M. Tsai, IgE and mast cells in allergic disease, *Nature medicine* 18 (5) (2012) 693–704.
- [50] R. Silver, J.P. Curley, Mast cells on the mind: new insights and opportunities, *Trends in neurosciences* 36 (9) (2013) 513–521.
- [51] S.J. Galli, J. Wedemeyer, M. Tsai, Analyzing the roles of mast cells and basophils in host defense and other biological responses, *International journal of hematology* 75 (4) (2002) 363–369.
- [52] L. Ramos, G. Peña, B. Cai, E. Deitch, L. Ulloa, Mast cell stabilization improves survival by preventing apoptosis in sepsis, *The Journal of Immunology* 185 (1) (2010) 709–716.
- [53] M. Urb, D.C. Sheppard, The role of mast cells in the defence against pathogens, *PLoS pathogens* 8 (4) (2012) e1002619.
- [54] K. Norrby, Mast cells and angiogenesis, *Apmis* 110 (5) (2002) 355–371.
- [55] S.C. Bischoff, S. Schwengberg, R. Raab, M.P. Manns, Functional properties of human intestinal mast cells cultured in a new culture system: enhancement of IgE receptor-dependent mediator release and response to stem cell factor, *The Journal of Immunology* 159 (11) (1997) 5560–5567.
- [56] J. Douaiher, J. Succar, L. Lancerotto, M.F. Gurish, D.P. Orgill, M.J. Hamilton, S.A. Krilis, R.L. Stevens, Development of mast cells and importance of their trypsinase and chymase serine proteases in inflammation and wound healing, *Advances in immunology* 122 (2014) 211.
- [57] C. Benoist, D. Mathis, Mast cells in autoimmune disease, *Nature* 420 (6917) (2002) 875–878.
- [58] B.F. Gibbs, M. Ennis, Isolation and purification of human mast cells and basophils, *Human Airway Inflammation: Sampling Techniques and Analytical Protocols* (2001) 161–176.
- [59] G. Selge, S.C. Bischoff, Isolation, culture, and characterization of intestinal mast cells, *Mast Cells: Methods and Protocols* (2005) 123–138.
- [60] Y. Wang, Z. Zhao, Z. Ren, B. Zhao, L. Zhang, J. Chen, W. Xu, S. Lu, Q. Zhao, J. Peng, Recellularized nerve allografts with differentiated mesenchymal stem cells promote peripheral nerve regeneration, *Neuroscience Letters* 514 (1) (2012) 96–101.
- [61] S. Rafii, D. Lyden, Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration, *Nature medicine* 9 (6) (2003) 702–712.
- [62] B. Bonandrini, M. Figliuzzi, E. Papadimou, M. Morigi, N. Perico, F. Casiraghi, F. Galligani, S. Conti, A. Benigni, A. Remuzzi, Recellularization of well-preserved acellular kidney scaffold using embryonic stem cells, *Tissue Engineering Part A* 20 (9–10) (2014) 1486–1498.
- [63] S.D. Schwartz, J.-P. Hubschman, G. Heilwell, V. Franco-Cardenas, C.K. Pan, R.M. Ostreck, E. Mickunas, R. Gay, I. Klimanskaya, R. Lanza, Embryonic stem cell trials for macular degeneration: a preliminary report, *The Lancet* 379 (9817) (2012) 713–720.
- [64] A. Brederlau, A.S. Correia, S.V. Anisimov, M. Elmi, G. Paul, L. Roybon, A. Morizane, F. Bergquist, I. Riebe, U. Nannmark, Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation, *Stem cells* 24 (6) (2006) 1433–1440.
- [65] R. Gonzalez, I. Garitaonandia, A. Crain, M. Poustovoitov, T. Abramihina, A. Noskov, C. Jiang, R. Morey, L.C. Laurent, J.D. Elsworth, Proof of concept studies exploring the safety and functional activity of human parthenogenetic-derived neural stem cells for the treatment of Parkinson's disease, *Cell transplantation* 24 (4) (2015) 681–690.
- [66] P.A. Lalit, D.J. Hei, A.N. Raval, T.J. Kamp, Induced Pluripotent Stem Cells for Post-Myocardial Infarction Repair, *Circulation research* 114 (8) (2014) 1328–1345.
- [67] M. Khan, E. Nickoloff, T. Abramova, J. Johnson, S.K. Verma, P. Krishnamurthy, A.R. Mackie, E. Vaughan, V.N. Garikipati, C.L. Benedict, Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction, *Circulation research* 115 (2015) 305990 CIRCRESAHA.
- [68] C.M. Baum, L.L. Weissman, A.S. Tsukamoto, A.-M. Buckle, B. Peault, Isolation of a candidate human hematopoietic stem-cell population, *Proceedings of the National Academy of Sciences* 89 (7) (1992) 2804–2808.
- [69] K. Schriehl, S. Lim, A. Choo, A. Tscheliessnig, A. Jungbauer, Stem cell separation: a bottleneck in stem cell therapy, *Biotechnology journal* 5 (1) (2010) 50–61.
- [70] A.P. Jillella, C. Ustun, What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant? *Stem cells and development* 13 (6) (2004) 598–606.
- [71] I. Klimanskaya, N. Rosenthal, R. Lanza, Derive and conquer: sourcing and dif-

- ferentiating stem cells for therapeutic applications, *Nature reviews Drug discovery* 7 (2) (2008) 131–142.
- [72] G.I. Nistor, M.O. Totoiu, N. Haque, M.K. Carpenter, H.S. Keirstead, Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation, *Glia* 49 (3) (2005) 385–396.
- [73] D. Doi, B. Samata, M. Katsukawa, T. Kikuchi, A. Morizane, Y. Ono, K. Sekiguchi, M. Nakagawa, M. Parmar, J. Takahashi, Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation, *Stem cell reports* 2 (3) (2014) 337–350.
- [74] T.A. Juopperi, W. Schuler, X. Yuan, M.I. Collector, C.V. Dang, S.J. Sharkis, Isolation of bone marrow-derived stem cells using density-gradient separation, *Experimental hematology* 35 (2) (2007) 335–341.
- [75] Y. Yamamoto, S. Itoh, Y. Yamauchi, K. Matsushita, S. Ikeda, H. Naruse, M. Hayashi, Density Gradient Centrifugation for the Isolation of Cells of Multiple Lineages, *Journal of cellular biochemistry* 116 (12) (2015) 2709–2714.
- [76] R.L. Rietze, H. Valcanis, G.F. Brooker, T. Thomas, A.K. Voss, P.F. Bartlett, Purification of a pluripotent neural stem cell from the adult mouse brain, *Nature* 412 (6848) (2001) 736–739.
- [77] S. Philipp, H.H. Oberg, O. Janssen, M. Leippe, C. Gelhaus, Isolation of erythrocytes infected with viable early stages of *Plasmodium falciparum* by flow cytometry, *Cytometry Part A* 81 (12) (2012) 1048–1054.
- [78] S. Tohyama, F. Hattori, M. Sano, T. Hishiki, Y. Nagahata, T. Matsuura, H. Hashimoto, T. Suzuki, H. Yamashita, Y. Satoh, Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes, *Cell stem cell* 12 (1) (2013) 127–137.
- [79] M.M. Ferreira, V.C. Ramani, S.S. Jeffrey, Circulating tumor cell technologies, *Molecular oncology* 10 (3) (2016) 374–394.
- [80] P. Bankó, S.Y. Lee, V. Nagygyörgy, M. Zrínyi, C.H. Chae, D.H. Cho, A. Telekes, Technologies for circulating tumor cell separation from whole blood, *Journal of hematology & oncology* 12 (1) (2019) 48.
- [81] H.D. Lu, S.S. Yang, B.K. Wilson, S.A. McManus, C.V.-H. Chen, R.K. Prud'homme, Nanoparticle targeting of Gram-positive and Gram-negative bacteria for magnetic-based separations of bacterial pathogens, *Applied Nanoscience* 7 (3–4) (2017) 83–93.
- [82] N.J. Nelson, Circulating tumor cells: will they be clinically useful?, Oxford University Press, 2010.
- [83] J. Kim, M. Massoudi, J.F. Antaki, A. Gandini, Removal of malaria-infected red blood cells using magnetic cell separators: A computational study, *Applied mathematics and computation* 218 (12) (2012) 6841–6850.
- [84] A. Gandini, R. Weinstein, R.-p. Sawh, D. Parks, Blood purification method and apparatus for the treatment of malaria, Google Patents (2013).
- [85] J. Nam, H. Huang, H. Lim, C. Lim, S. Shin, Magnetic separation of malaria-infected red blood cells in various developmental stages, *Analytical chemistry* 85 (15) (2013) 7316–7323.
- [86] A. Deshpande, S. Kalgutkar, S. Udani, Red cell exchange using cell separator (therapeutic erythrocytapheresis) in two children with acute severe malaria, *JOURNAL-ASSOCIATION OF PHYSICIANS OF INDIA* 51 (2003) 925–926.
- [87] A.B. Martin, W.-T. Wu, M.V. Kameneva, J.F. Antaki, Development of a high-throughput magnetic separation device for malaria-infected erythrocytes, *Annals of biomedical engineering* 45 (12) (2017) 2888–2898.
- [88] M. Stevenson, T. Stanwick, M. Dempsey, C. Lamonica, HIV-1 replication is controlled at the level of T cell activation and proviral integration, *The EMBO journal* 9 (5) (1990) 1551.
- [89] D.P. Collins, B.J. Luebering, D.M. Shaut, T-lymphocyte functionality assessed by analysis of cytokine receptor expression, intracellular cytokine expression, and femtomolar detection of cytokine secretion by quantitative flow cytometry, *Cytometry Part A* 33 (2) (1998) 249–255.
- [90] K. El-Boubbou, C. Gruden, X. Huang, Magnetic glyco-nanoparticles: a unique tool for rapid pathogen detection, decontamination, and strain differentiation, *Journal of the American Chemical Society* 129 (44) (2007) 13392–13393.
- [91] G. Cai, S. Wang, L. Zheng, J. Lin, A fluidic device for immunomagnetic separation of foodborne bacteria using self-assembled magnetic nanoparticle chains, *Micromachines* 9 (12) (2018) 624.
- [92] L.L. Matta, E.C. Alocilja, Carbohydrate Ligands on Magnetic Nanoparticles for Centrifuge-Free Extraction of Pathogenic Contaminants in Pasteurized Milk, *Journal of food protection* 81 (12) (2018) 1941–1949.
- [93] M. Dainiak, A. Kumar, I. Galaev, B. Mattiasson, Methods in cell separations, *Cell Separation* (2007) 1–18.
- [94] T.G. Pretlow, T.P. Pretlow, Cell separation: methods and selected applications, Academic Press, 2014.
- [95] M.K. Brakke, Density gradient centrifugation: a new separation technique, *Journal of the American Chemical Society* 73 (4) (1951) 1847–1848.
- [96] G.J. Brewer, J.R. Torricelli, Isolation and culture of adult neurons and neurospheres, *Nature protocols* 2 (6) (2007) 1490–1498.
- [97] N.R. Sims, M.F. Anderson, Isolation of mitochondria from rat brain using Percoll density gradient centrifugation, *Nature protocols* 3 (7) (2008) 1228–1239.
- [98] Y. Chang, P.-H. Hsieh, C.C. Chao, The efficiency of Percoll and Ficoll density gradient media in the isolation of marrow derived human mesenchymal stem cells with osteogenic potential, *Chang Gung Med J* 32 (3) (2009) 264–275.
- [99] I.J. Fuss, M.E. Kanof, P.D. Smith, H. Zola, Isolation of whole mononuclear cells from peripheral blood and cord blood, Wiley Online Library 2009.
- [100] B. Zhu, S.K. Murthy, Stem cell separation technologies, *Current opinion in chemical engineering* 2 (1) (2013) 3–7.
- [101] Y. Huang, J. Yang, X.-B. Wang, F.F. Becker, P.R. Gascoyne, The removal of human breast cancer cells from hematopoietic CD34+ stem cells by dielectrophoretic field-flow-fractionation, *Journal of hematology & stem cell research* 8 (5) (1999) 481–490.
- [102] X.-B. Wang, J. Yang, Y. Huang, J. Vykoukal, F.F. Becker, P.R. Gascoyne, Cell separation by dielectrophoretic field-flow-fractionation, *Analytical Chemistry* 72 (4) (2000) 832–839.
- [103] M. Elitas, N. Dhar, K. Schneider, A. Valero, T. Braschler, J. McKinney, P. Renaud, Dielectrophoresis as a single cell characterization method for bacteria, *Biomedical Physics & Engineering Express* 3 (1) (2017) 015005.
- [104] R.E. Fernandez, A. Rohani, V. Farmehini, N.S. Swami, Microbial analysis in dielectrophoretic microfluidic systems, *Analytica chimica acta* 966 (2017) 11–33.
- [105] J. Zhang, Z. Song, Q. Liu, Y. Song, Recent Advances in Dielectrophoresis-Based Cell Viability Assessment, *Electrophoresis* (2019).
- [106] P. Reschiglian, A. Zattoni, B. Roda, E. Michelini, A. Roda, Field-flow fractionation and biotechnology, *TRENDS in Biotechnology* 23 (9) (2005) 475–483.
- [107] J. Vykoukal, D.M. Vykoukal, S. Freyberg, E.U. Alt, P.R. Gascoyne, Enrichment of putative stem cells from adipose tissue using dielectrophoretic field-flow fractionation, *Lab on a Chip* 8 (8) (2008) 1386–1393.
- [108] B. Roda, G. Lanzoni, F. Alviano, A. Zattoni, R. Costa, A. Di Carlo, C. Marchionni, M. Franchina, F. Ricci, P.L. Tazzari, A novel stem cell tag-less sorting method, *Stem Cell Reviews and Reports* 5 (4) (2009) 420–427.
- [109] B. Roda, P. Reschiglian, F. Alviano, G. Lanzoni, G.P. Bagnara, F. Ricci, M. Buzzi, P.L. Tazzari, P. Pagliaro, E. Michelini, Gravitational field-flow fractionation of human hemopoietic stem cells, *Journal of Chromatography A* 1216 (52) (2009) 9081–9087.
- [110] B. Roda, A. Zattoni, P. Reschiglian, M.H. Moon, M. Mirasoli, E. Michelini, A. Roda, Field-flow fractionation in bioanalysis: a review of recent trends, *Analytica chimica acta* 635 (2) (2009) 132–143.
- [111] T. Chianea, N. Assidjo, P. Cardot, Sedimentation field-flow-fractionation: emergence of a new cell separation methodology, *Talanta* 51 (5) (2000) 835–847.
- [112] S. Choi, S. Song, C. Choi, J.-K. Park, Continuous blood cell separation by hydrophoretic filtration, *Lab on a Chip* 7 (11) (2007) 1532–1538.
- [113] X. Chen, C.C. Liu, H. Li, Microfluidic chip for blood cell separation and collection based on crossflow filtration, *Sensors and Actuators B: Chemical* 130 (1) (2008) 216–221.
- [114] J. Li, C. Liu, X. Dai, H. Chen, Y. Liang, H. Sun, H. Tian, X. Ding, PMMA microfluidic devices with three-dimensional features for blood cell filtration, *Journal of Micromechanics and Microengineering* 18 (9) (2008) 095021.
- [115] S.M. McFaul, B.K. Lin, H. Ma, Cell separation based on size and deformability using microfluidic funnel ratchets, *Lab on a chip* 12 (13) (2012) 2369–2376.
- [116] B. Cunha, C. Peixoto, M.M. Silva, M.J. Carrondo, M. Serra, P.M. Alves, Filtration methodologies for the clarification and concentration of human mesenchymal stem cells, *Journal of membrane science* 478 (2015) 117–129.
- [117] N. Bordag, V. Janakiraman, J. Nachtigall, S.G. Maldonado, B. Bethan, J.-P. Laine, E. Fux, Fast filtration of bacterial or mammalian suspension cell cultures for optimal metabolomics results, *PLoS one* 11 (7) (2016).
- [118] S. Ribeiro-Samy, M.I. Oliveira, T. Pereira-Veiga, L. Muñelo-Romay, S. Carvalho, J. Gaspar, P.P. Freitas, R. López-López, C. Costa, L. Diéguez, Fast and efficient microfluidic cell filter for isolation of circulating tumor cells from unprocessed whole blood of colorectal cancer patients, *Scientific reports* 9 (1) (2019) 1–12.
- [119] E. Binda, D. Erhart, M. Schenk, C. Zufferey, P. Renzulli, C. Mueller, Quantitative isolation of mouse and human intestinal intraepithelial lymphocytes by elutriation centrifugation, *Journal of immunological methods* 344 (1) (2009) 26–34.
- [120] J. Grosse, K. Meier, T.J. Bauer, C. Eilles, D. Grimm, Cell separation by counter-current centrifugal elutriation: recent developments, *Preparative Biochemistry and Biotechnology* 42 (3) (2012) 217–233.
- [121] D.F. Stroneck, V. Fellowes, C. Pham, H. Khuu, D.H. Fowler, L.V. Wood, M. Sabatino, Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapies, *Journal of translational medicine* 12 (1) (2014) 241.
- [122] J. Bauer, Advances in cell separation: recent developments in counterflow centrifugal elutriation and continuous flow cell separation, *Journal of Chromatography B: Biomedical Sciences and Applications* 722 (1–2) (1999) 55–69.
- [123] J. Lasch, G. Küllertz, J.R. Opalka, Separation of erythrocytes into age-related fractions by density or size? Counterflow centrifugation, *Clinical chemistry and laboratory medicine* 38 (7) (2000) 629–632.
- [124] D.R. Gossett, W.M. Weaver, A.J. Mach, S.C. Hur, H.T.K. Tse, W. Lee, H. Amini, D. Di Carlo, Label-free cell separation and sorting in microfluidic systems, *Analytical and bioanalytical chemistry* 397 (8) (2010) 3249.
- [125] T. Yeo, S.J. Tan, C.L. Lim, D.P.X. Lau, Y.W. Chua, S.S. Krishna, G. Iyer, G. San Tan, T.K.H. Lim, D.S. Tan, Microfluidic enrichment for the single cell analysis of circulating tumor cells, *Scientific reports* 6 (2016) 22076.
- [126] C. Pösel, K. Möller, W. Fröhlich, I. Schulz, J. Boltze, D.-C. Wagner, Density gradient centrifugation compromises bone marrow mononuclear cell yield, *PLoS one* 7 (12) (2012) e50293.
- [127] K. Wang, M.K. Marshall, G. Garza, D. Pappas, Open-tubular capillary cell affinity chromatography: single and tandem blood cell separation, *Analytical chemistry* 80 (6) (2008) 2118–2124.
- [128] A. Kumar, A. Srivastava, Cell separation using cryogel-based affinity chromatography, *Nature protocols* 5 (11) (2010) 1737–1747.
- [129] P. Li, Y. Gao, D. Pappas, Multiparameter cell affinity chromatography: separation and analysis in a single microfluidic channel, *Analytical chemistry* 84 (19) (2012) 8140–8148.
- [130] B.J. Tauro, D.W. Greening, R.A. Mathias, H. Ji, S. Mathivanan, A.M. Scott,

- R.J. Simpson, Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes, *Methods* 56 (2) (2012) 293–304.
- [131] Y. Gao, W. Li, D. Pappas, Recent advances in microfluidic cell separations, *Analyst* 138 (17) (2013) 4714–4721.
- [132] N. Labrou, Y. Clonis, The affinity technology in downstream processing, *Journal of biotechnology* 36 (2) (1994) 95–119.
- [133] S. Menegatti, A.D. Naik, R.G. Carbonell, The hidden potential of small synthetic molecules and peptides as affinity ligands for bioseparations, *Pharmaceutical Bioprocessing* 1 (5) (2013) 467–485.
- [134] G. Rodrigues, T. Fernandes, C. Rodrigues, M. Diogo, J. Cabral, Enrichment and Separation Technologies for Stem Cell-Based Therapies, *Stem Cell Manufacturing* (2016) 199.
- [135] M.A. Hoeve, P.A. De Sousa, N.A. Willoughby, Challenges of Scale-up of Cell Separation and Purification Techniques, *Bioprocessing for Cell-Based Therapies* (2017) 127.
- [136] N. Rahmiani, M. Bozorgmehr, M. Torabi, A. Akbari, A.-H. Zarnani, Cell separation: Potentials and pitfalls, *Preparative Biochemistry and Biotechnology* 47 (1) (2017) 38–51.
- [137] J. Wu, Q. Chen, J.-M. Lin, Microfluidic technologies in cell isolation and analysis for biomedical applications, *Analyst* 142 (3) (2017) 421–441.
- [138] J. Hubble, Affinity cell separations: problems and prospects, *Trends in Biotechnology* 15 (7) (1997) 249–255.
- [139] X. Cao, R. Eisinger, J. Hubble, Detachment strategies for affinity-adsorbed cells, *Enzyme and microbial technology* 31 (1) (2002) 153–160.
- [140] A. Kumar, I.Y. Galaev, B. Mattiasson, *Cell Separation: Fundamentals, Analytical and Preparative Methods*, Springer Berlin Heidelberg 2010.
- [141] S. Rawal, Y.-P. Yang, R. Cote, A. Agarwal, Identification and Quantitation of Circulating Tumor Cells, *Annual Review of Analytical Chemistry* (0) (2017).
- [142] J.J. Chalmers, M. Zborowski, L. Moore, S. Mandal, B. Fang, L. Sun, Theoretical analysis of cell separation based on cell surface marker density, *Biotechnology and bioengineering* 59 (1) (1998) 10–20.
- [143] A. Mahara, T. Yamaoka, Antibody-immobilized column for quick cell separation based on cell rolling, *Biotechnology progress* 26 (2) (2010) 441–447.
- [144] F.S. Lakschevitz, S. Hassanpour, A. Rubin, N. Fine, C. Sun, M. Glogauer, Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry, *Experimental cell research* 342 (2) (2016) 200–209.
- [145] T. Yamaoka, A. Mahara, Cell rolling column in purification and differentiation analysis of stem cells, *Reactive and Functional Polymers* 71 (3) (2011) 362–366.
- [146] C.F. Cahall, J.L. Lilly, E.A. Hirschowitz, B.J. Berron, A Quantitative Perspective on Surface Marker Selection for the Isolation of Functional Tumor Cells, *Breast cancer: basic and clinical research* 9 (Suppl 1) (2015) 1.
- [147] C. Mavrougelos, B. Swart, S. Nobbs, L.C. Nicholson, P.J. Macardle, H. Zola, Detection of low-abundance membrane markers by immunofluorescence—a comparison of alternative high-sensitivity methods and reagents, *Journal of immunological methods* 289 (1) (2004) 169–178.
- [148] D. Mattanovich, N. Borth, Applications of cell sorting in biotechnology, *Microbial cell factories* 5 (1) (2006) 12.
- [149] B. Will, U. Steidl, Multi-parameter fluorescence-activated cell sorting and analysis of stem and progenitor cells in myeloid malignancies, *Best Practice & Research Clinical Haematology* 23 (3) (2010) 391–401.
- [150] M.J. Tomlinson, S. Tomlinson, X.B. Yang, J. Kirkham, Cell separation: Terminology and practical considerations, *Journal of tissue engineering* 4 (2013) 2041731412472690.
- [151] A. Raj, A. van Oudenaarden, Nature, nurture, or chance: stochastic gene expression and its consequences, *Cell* 135 (2) (2008) 216–226.
- [152] P. Cahan, G.Q. Daley, Origins and implications of pluripotent stem cell variability and heterogeneity, *Nature reviews Molecular cell biology* 14 (6) (2013) 357–368.
- [153] Y. Ohnishi, W. Huber, A. Tsumura, M. Kang, P. Xenopoulos, K. Kurimoto, A.K. Oleś, M.J. Araúzo-Bravo, M. Saitou, A.-K. Hadjantonakis, Cell-to-cell expression variability followed by signal reinforcement progressively segregates early mouse lineages, *Nature cell biology* 16 (1) (2014) 27–37.
- [154] S.-H. Hong, S. Rampalli, J.B. Lee, J. McNicol, T. Collins, J.S. Draper, M. Bhatia, Cell fate potential of human pluripotent stem cells is encoded by histone modifications, *Cell stem cell* 9 (1) (2011) 24–36.
- [155] T.Y. Lee, K.-A. Hyun, S.-I. Kim, H.-I. Jung, An integrated microfluidic chip for one-step isolation of circulating tumor cells, *Sensors and Actuators B: Chemical* 238 (2017) 1144–1150.
- [156] C.-L. Chen, K.-C. Chen, Y.-C. Pan, T.-P. Lee, L.-C. Hsiung, C.-M. Lin, C.-Y. Chen, C.-H. Lin, B.-L. Chiang, A.M. Wo, Separation and detection of rare cells in a microfluidic disk via negative selection, *Lab on a Chip* 11 (3) (2011) 474–483.
- [157] K.-A. Hyun, H.-I. Jung, Advances and critical concerns with the microfluidic enrichments of circulating tumor cells, *Lab on a Chip* 14 (1) (2014) 45–56.
- [158] J. Bu, Y.-T. Kang, Y.J. Kim, Y.-H. Cho, H.J. Chang, H. Kim, B.-I. Moon, H.G. Kim, Dual-patterned immunofiltration (DIF) device for the rapid efficient negative selection of heterogeneous circulating tumor cells, *Lab on a Chip* 16 (24) (2016) 4759–4769.
- [159] P. Li, Y. Gao, D. Pappas, Negative enrichment of target cells by microfluidic affinity chromatography, *Analytical chemistry* 83 (20) (2011) 7863–7869.
- [160] B.N.G. Sajay, C.-P. Chang, H. Ahmad, P. Khuntontong, C.C. Wong, Z. Wang, P.D. Pui, R. Soo, A.R.A. Rahman, Microfluidic platform for negative enrichment of circulating tumor cells, *Biomed. Microdevices* 16 (4) (2014) 537–548.
- [161] K. Masson, E. Heiss, H. Band, L. Rönstrand, Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation, *Biochemical journal* 399 (1) (2006) 59–67.
- [162] G. Krishnaswamy, O. Ajitawi, D.S. Chi, The human mast cell: an overview, *Mast Cells: Methods and Protocols* (2005) 13–34.
- [163] Y. Liu, X. Tang, F. Liu, K.A. Li, Selection of ligands for affinity chromatography using quartz crystal biosensor, *Analytical chemistry* 77 (13) (2005) 4248–4256.
- [164] A. Drabovich, *Selection of Affinity Ligands Using Kinetic Capillary Electrophoresis*, York University 2008.
- [165] C. Bergsdorf, J. Ottl, Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads, *Expert opinion on drug discovery* 5 (11) (2010) 1095–1107.
- [166] Y. Wei, P.J. Wesson, I. Kourkine, B.A. Grzybowski, Measurement of Protein–Ligand Binding Constants from Reaction-Diffusion Concentration Profiles, *Analytical chemistry* 82 (21) (2010) 8780–8784.
- [167] M. Mammen, S.-K. Choi, G.M. Whitesides, Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors, *Angewandte Chemie International Edition* 37 (20) (1998) 2754–2794.
- [168] M. Mourez, R.S. Kane, J. Mogridge, S. Metallo, P. Deschatelets, B.R. Sellman, G.M. Whitesides, R.J. Collier, Designing a polyvalent inhibitor of anthrax toxin, *Nature biotechnology* 19 (10) (2001) 958–961.
- [169] P. Adler, S.J. Wood, Y.C. Lee, R.T. Lee, W.A. Petri, R.L. Schnaar, High affinity binding of the *Entamoeba histolytica* lectin to polyvalent N-acetylgalactosaminides, *Journal of biological chemistry* 270 (10) (1995) 5164–5171.
- [170] G. Brown, M.F. Greaves, Cell surface markers for human T and B lymphocytes, *European journal of immunology* 4 (4) (1974) 302–310.
- [171] S.K. Sharma, P. Mahendroo, Affinity chromatography of cells and cell membranes, *Journal of Chromatography A* 184 (4) (1980) 471–499.
- [172] R.S. Basch, J.W. Berman, E. Lakow, Cell separation using positive immunoselective techniques, *Journal of immunological methods* 56 (3) (1983) 269–280.
- [173] K.R. Tadikonda, R.H. Davis, Cell separations using targeted monoclonal antibodies against overproduced surface proteins, *Applied biochemistry and biotechnology* 45 (1) (1994) 233–244.
- [174] S.M. Gomez, G. Choy, N. Kabir, E.F. Leonard, Capture of Rare Cells in Suspension with Antibody-Coated Polystyrene Beads, *Biotechnology progress* 15 (2) (1999) 238–244.
- [175] A. Sin, S.K. Murthy, A. Revzin, R.G. Tompkins, M. Toner, Enrichment using antibody-coated microfluidic chambers in shear flow: Model mixtures of human lymphocytes, *Biotechnology and bioengineering* 91 (7) (2005) 816–826.
- [176] W.H. Evans, M.G. Mage, E.A. Peterson, A Method for the Immunoadsorption of Cells to an Antibodycoated Polyurethane Foam, *The Journal of Immunology* 102 (4) (1969) 899–907.
- [177] H. Wigzell, K. Sundqvist, T.O. Yoshida, Separation of Cells According to Surface Antigens by the Use of Antibody-Coated Columns. Fractionation of Cells Carrying Immunoglobulins and Blood Group Antigen, *Scandinavian journal of immunology* 1 (1) (1972) 75–87.
- [178] H. Binz, H. Wigzell, Shared idiotypic determinants on B and T lymphocytes reactive against the same antigenic determinants. III. Physical fractionation of specific immunocompetent T lymphocytes by affinity chromatography using anti-idiotypic antibodies, *Journal of Experimental Medicine* 142 (5) (1975) 1231–1240.
- [179] J.D. Brewster, Isolation and concentration of *Salmonellae* with an immunoaffinity column, *Journal of microbiological methods* 55 (1) (2003) 287–293.
- [180] R.J. Berenson, L.J. Levitt, R. Levy, R.A. Miller, CELLULAR IMMUNOABSORPTION USING MONOCLONAL ANTIBODIES: ELECTIVE REMOVAL OF T CELLS FROM PERIPHERAL BLOOD AND BONE MARROW, *Transplantation* 38 (2) (1984) 136–142.
- [181] R.A. Hubbard, S.F. Schluter, J.J. Marchalonis, [14]Separation of lymphoid cells using immunoabsorbent affinity chromatography, *Methods in enzymology* 108 (1984) 139–148.
- [182] T. Uchiyama, T. Hori, M. Tsudo, Y. Wano, H. Umadome, S. Tamori, J. Yodoi, M. Maeda, H. Sawami, H. Uchino, Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells, *Journal of Clinical Investigation* 76 (2) (1985) 446.
- [183] R.W. Braun, G. Kümel, [70]Separation of T cell subpopulations by monoclonal antibodies and affinity chromatography, *Methods in enzymology* 121 (1986) 737–748.
- [184] K. Kataoka, Y. Sakurai, T. Hanai, A. Maruyama, T. Tsuruta, Immunoaffinity chromatography of lymphocyte subpopulations using tert-amine derived matrices with adsorbed antibodies, *Biomaterials* 9 (3) (1988) 218–224.
- [185] T.E. Thomas, P.M. Lansdorp, Immunoadsorption of T cells onto glass beads using tetramolecular complexes of monoclonal antibodies, *Journal of immunological methods* 112 (2) (1988) 219–226.
- [186] E.S. Schulman, D.W. MacGLASHAN, S.P. Peters, R. Schleimer, H. Newball, L. Lichtenstein, Human lung mast cells: purification and characterization, *The Journal of Immunology* 129 (6) (1982) 2662–2667.
- [187] F. Van Overveld, P. Bruijnzeel, J. Kreukniet, J. Raaijmakers, G. Terpstra, The isolation of inflammatory cells from normal human lung tissue, *International journal of tissue reactions* 9 (1) (1986) 61–67.
- [188] A.M.-J. Au, S. Varon, Neural cell sequestration on immunoaffinity columns, *Experimental cell research* 120 (2) (1979) 269–276.
- [189] D. Chatterjee, C. Mandal, P. Sarkar, Development and characterization of five monoclonal antibodies against neuronal cell surface antigens—Evaluation of

- their use in cell separation by affinity chromatography, *Journal of neuroimmunology* 15 (3) (1987) 251–262.
- [190] M. Körbling, J. Drach, R. Champlin, H. Engel, L. Huynh, H. Kleine, R. Berenson, A. Deisseroth, M. Andreeff, Large-scale preparation of highly purified, frozen/thawed CD34+, HLA-DR-hematopoietic progenitor cells by sequential immunoadsorption (CEPRATE SC) and fluorescence-activated cell sorting: implications for gene transduction and/or transplantation, *Bone marrow transplantation* 13 (5) (1994) 649–654.
- [191] A.W. Wognum, A.C. Eaves, T.E. Thomas, Identification and isolation of hematopoietic stem cells, *Archives of medical research* 34 (6) (2003) 461–475.
- [192] A. Mahara, T. Yamaoka, Continuous separation of cells of high osteoblastic differentiation potential from mesenchymal stem cells on an antibody-immobilized column, *Biomaterials* 31 (14) (2010) 4231–4237.
- [193] G.L. Manderino, G.T. Gooch, A.B. Stavitsky, Preparation, characterization, and functions of rabbit lymph node cell populations: I. Preparation of KLH primed T and B memory cells with anti-Fab' affinity columns, *Cellular immunology* 41 (2) (1978) 264–275.
- [194] P.L. Romain, S.F. Schlossman, [15]Use of anti-fab columns for the isolation of human lymphocyte populations, *Methods in enzymology* 108 (1984) 148–153.
- [195] R. Braun, H. Teute, H. Kirchner, K. Munk, Rapid separation of T cell subpopulations with monoclonal antibodies and affinity chromatography, *Journal of immunological methods* 54 (2) (1982) 251–258.
- [196] H. Firat, M. Giarratana, L. Kobari, A. Poloni, S. Bouchet, M. Labopin, N. Gorin, L. Douay, Comparison of CD34+ bone marrow cells purified by immunomagnetic and immunoadsorption cell separation techniques, *Bone marrow transplantation* 21 (9) (1998) 933–938.
- [197] D. Thomas, B. Phillips, The separation of human B lymphocytes on a digestible immunoadsorbent column, *European journal of immunology* 3 (11) (1973) 740–742.
- [198] T.E. Thomas, H.J. Sutherland, P.M. Lansdorp, Specific binding and release of cells from beads using cleavable tetrameric antibody complexes, *Journal of immunological methods* 120 (2) (1989) 221–231.
- [199] K.A. Zettlitz, Protein A/G Chromatography, *Antibody Engineering* (2010) 531–535.
- [200] A. Nash, Separation of lymphocyte sub-populations using antibodies attached to staphylococcal protein A-coated surfaces, *Journal of immunological methods* 12 (1–2) (1976) 149–161.
- [201] V. Ghetie, G. Mota, J. Sjöquist, Separation of cells by affinity chromatography on SpA-Sepharose 6MB, *Journal of immunological methods* 21 (1–2) (1978) 133–141.
- [202] T. Kretzer, J. Bodmer, W. Bodmer, The separation of cell populations using monoclonal antibodies attached to sepharose, *HLA* 16 (4) (1980) 317–325.
- [203] V. Ghetie, J. Sjöquist, [13]Separation of cells by affinity chromatography on protein A gels, *Methods in enzymology* 108 (1984) 132–138.
- [204] A. Kumar, F.M. Plieva, I.Y. Galaev, B. Mattiasson, Affinity fractionation of lymphocytes using a monolithic cryogel, *Journal of immunological methods* 283 (1) (2003) 185–194.
- [205] A. Kumar, A. Rodríguez-Caballero, F.M. Plieva, I.Y. Galaev, K.S. Nandakumar, M. Kamihira, R. Holmdahl, A. Orfao, B. Mattiasson, Affinity binding of cells to cryogel adsorbents with immobilized specific ligands: effect of ligand coupling and matrix architecture, *Journal of Molecular Recognition* 18 (1) (2005) 84–93.
- [206] V. Ghetie, G. Stålenheim, J. Sjöquist, Cell Separation by Staphylococcal Protein A-Coated Erythrocytes, *Scandinavian journal of immunology* 4 (5) (1975) 471–477.
- [207] D. Levitt, R. Danen, Separation of lymphocyte subpopulations using biotin-avidin erythrocyte rosettes, *Journal of immunological methods* 89 (2) (1986) 207–211.
- [208] P.S. Duffey, D.L. Drouillard, C.P. Barbe, Lymphocyte sorting on albuminated CIBA blue dextran-staphylococcal protein A-conjugated sepharose 6MB affinity columns, *Journal of immunological methods* 45 (2) (1981) 137–151.
- [209] H. Wigzell, C. Huber, V. Schirmacher, Affinity fractionation of lymphoid cells according to type and function, *Haematologia* 6 (3) (1972) 369–375.
- [210] D. DeLuca, R.L. Yowell, A. Miller, The specific separation of enzyme antigen-binding cells by substrate affinity chromatography, *Microenvironmental Aspects of Immunity*, Springer, 1973, pp. 693–698.
- [211] I. MacLennan, D. Gray, Antigen-driven selection of virgin and memory B cells, *Immunological reviews* 91 (1) (1986) 61–86.
- [212] H. Wigzell, B. Andersson, Cell separation on antigen-coated columns, *Journal of Experimental Medicine* 129 (1) (1969) 23–36.
- [213] R.E. Carvajal, F.M. Porras, F. García-Carreño, Separation and isolation of lymphocyte subpopulations of different affinity for the antigen, *Immunology letters* 8 (2) (1984) 101–106.
- [214] P. Truffa-Bachi, L. Wofsy, Specific separation of cells on affinity columns, *Proceedings of the National Academy of Sciences* 66 (3) (1970) 685–692.
- [215] L. Wofsy, J. Kimura, P. Truffa-Bachi, Cell separation on affinity columns: the preparation of pure populations of anti-hapten specific lymphocytes, *The Journal of Immunology* 107 (3) (1971) 725–729.
- [216] C. Henry, J. Kimura, L. Wofsy, Cell separation on affinity columns: the isolation of immunospecific precursor cells from unimmunized mice, *Proceedings of the National Academy of Sciences* 69 (1) (1972) 34–36.
- [217] W. Haas, J. Schrader, A. Szenberg, A new, simple method for the preparation of lymphocytes bearing specific receptors, *European journal of immunology* 4 (8) (1974) 565–570.
- [218] K. Kataoka, Y. Sakurai, T. Tsuruta, *Affinity Selection of Cells on Solid-Phase Matrices with Immobilized Proteins*, ACS Publications 1987.
- [219] C. Hertz, D. Graves, D. Lauffenburger, F. Serota, Use of cell affinity chromatography for separation of lymphocyte subpopulations, *Biotechnology and bioengineering* 27 (5) (1985) 603–612.
- [220] U. Hellström, M.-L. Hammarström, S. Hammarström, P. Perlmann, [16]Fractionation of human lymphocytes on Helix pomatia a hemagglutinin-sepharose and wheat germ agglutinin-sepharose, *Methods in enzymology* 108 (1984) 153–168.
- [221] D.D. Putnam, V. Namasivayam, M.A. Burns, Cell affinity separations using magnetically stabilized fluidized beds: Erythrocyte subpopulation fractionation utilizing a lectin-magnetite support, *Biotechnology and bioengineering* 81 (6) (2003) 650–665.
- [222] C. Whitehurst, N. Day, N. Gengozian, A method of purifying feline T lymphocytes from peripheral blood using the plant lectin from *Pisum sativum*, *Journal of immunological methods* 175 (2) (1994) 189–199.
- [223] J.-C. Bonnafous, J. Dornand, J. Favero, E. Boschetti, J.-C. Mani, Cell affinity chromatography with ligands immobilized through cleavable mercury-sulfur bonds, *Journal of immunological methods* 58 (1–2) (1983) 93–107.
- [224] H. Walter, *Partitioning in aqueous two-phase system: theory, methods, uses, and applications to biotechnology*, Elsevier 2012.
- [225] A. Thiel, A. Scheffold, A. Radbruch, Immunomagnetic cell sorting—pushing the limits, *Immunotechnology* 4 (2) (1998) 89–96.
- [226] S. Basu, H.M. Campbell, B.N. Dittel, A. Ray, Purification of specific cell population by fluorescence activated cell sorting (FACS), *Journal of visualized experiments: JoVE* 41 (2010).
- [227] K. Inaba, W.J. Swiggard, R.M. Steinman, N. Romani, G. Schuler, C. Brinster, Isolation of dendritic cells, *Current protocols in immunology* (7) (2009) 1–3 3.719.
- [228] M.E. Kanof, Isolation of T cells using rosetting procedures, *Current protocols in immunology* 112 (1) (2016) 1–7 7.2.2. 5.
- [229] T. Tondreau, L. Lagneaux, M. Dejenneff, A. Delforge, M. Massy, C. Mortier, D. Bron, Isolation of BM mesenchymal stem cells by plastic adhesion or negative selection: phenotype, proliferation kinetics and differentiation potential, *Cytotherapy* 6 (4) (2004) 372–379.
- [230] E.L. Reinherz, P.C. Kung, G. Goldstein, S.F. Schlossman, Separation of functional subsets of human T cells by a monoclonal antibody, *Proceedings of the National Academy of Sciences* 76 (8) (1979) 4061–4065.
- [231] T. Brody, Identification of two cell populations required for mouse immunocompetence, *The Journal of Immunology* 105 (1) (1970) 126–138.
- [232] C.S. Owen, E. Moore, High gradient magnetic separation of rosette-forming cells, *Cell Biochemistry and Biophysics* 3 (2) (1981) 141–153.
- [233] C.D. Myers, V.M. Sanders, E.S. Vitetta, Isolation of antigen-binding virgin and memory B cells, *Journal of immunological methods* 92 (1) (1986) 45–57.
- [234] M.B. Dainiak, I.Y. Galaev, A. Kumar, F.M. Plieva, B. Mattiasson, *Chromatography of living cells using supermacroporous hydrogels, cryogels*, Cell Separation, Springer, 2007, pp. 101–127.
- [235] F. Mohr, S. Przibilla, F. Leonhardt, C. Stemberger, S. Dreher, T.R. Müller, S.P. Fräße, G.P. Schmidt, M.-L. Kiene, H. Stadler, Efficient immunoaffinity chromatography of lymphocytes directly from whole blood, *Scientific reports* 8 (1) (2018) 1–6.
- [236] M. Wilchek, I. Chaiken, An overview of affinity chromatography, *Affinity Chromatography: Methods and Protocols* (2000) 1–6.
- [237] B.V. Ayyar, S. Arora, C. Murphy, R. O'Kennedy, Affinity chromatography as a tool for antibody purification, *Methods* 56 (2) (2012) 116–129.
- [238] D.A. Hammer, D.A. Lauffenburger, A dynamical model for receptor-mediated cell adhesion to surfaces, *Biophysical journal* 52 (3) (1987) 475–487.
- [239] D.A. Hammer, D.A. Lauffenburger, A dynamical model for receptor-mediated cell adhesion to surfaces in viscous shear flow, *Cell Biochemistry and Biophysics* 14 (2) (1989) 139–173.
- [240] C. Korn, U. Schwarz, Efficiency of initiating cell adhesion in hydrodynamic flow, *Physical review letters* 97 (13) (2006) 138103.
- [241] G. Vauquelin, S.J. Charlton, Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands, *British journal of pharmacology* 168 (8) (2013) 1771–1785.
- [242] G. Vauquelin, G. Bricca, I. Van Liefde, Avidity and positive allosteric modulation/cooperativity act hand in hand to increase the residence time of bivalent receptor ligands, *Fundamental & clinical pharmacology* 28 (5) (2014) 530–543.
- [243] M. Nauwerth, K. Wing, H. Korner, D. Busch, Relevance of the T cell Receptor-Ligand Avidity for Immunity to Infection, *J Microb Biochem Technol* 8 (2016) 131–135.
- [244] A. Saterbak, S.C. Kuo, D.A. Lauffenburger, Heterogeneity and probabilistic binding contributions to receptor-mediated cell detachment kinetics, *Biophysical journal* 65 (1) (1993) 243–252.
- [245] J. Hubble, R. Eisenthal, W.J. Whish, A model for the initial phase of cell/surface interactions based on ligand binding phenomena, *Biochemical Journal* 311 (3) (1995) 917–919.
- [246] J. Hubble, F. Ming, R. Eisenthal, W. Whish, Progressive detachment of cells from surfaces: A consequence of heterogeneous ligand populations or a multi-site binding equilibrium? *Journal of theoretical biology* 182 (2) (1996) 169–171.
- [247] F. Ming, W.J. Whish, J. Hubble, R. Eisenthal, Estimation of parameters for cell-surface interactions: maximum binding force and detachment constant, *Enzyme and microbial technology* 22 (2) (1998) 94–99.
- [248] F. Ming, R. Eisenthal, W.J. Whish, J. Hubble, The kinetics of affinity-mediated

- ated cell-surface attachment, *Enzyme and microbial technology* 26 (2) (2000) 216–221.
- [249] D.F. Tees, K.-C. Chang, S.D. Rodgers, D.A. Hammer, Simulation of cell adhesion to bioreactive surfaces in shear: The effect of cell size, *Industrial & engineering chemistry research* 41 (3) (2002) 486–493.
- [250] K.E. Caputo, D. Lee, M.R. King, D.A. Hammer, Adhesive dynamics simulations of the shear threshold effect for leukocytes, *Biophysical journal* 92 (3) (2007) 787–797.
- [251] D.A. Hammer, J.J. Linderman, D.J. Graves, D.A. Lauffenburger, Affinity chromatography for cell separation: mathematical model and experimental analysis, *Biotechnology progress* 3 (3) (1987) 189–204.
- [252] D.A. Hammer, D.A. Lauffenburger, Effects of nonspecific cell/surface interactions on cell affinity chromatographic separations, *MRS Online Proceedings Library Archive* (1987) 110.
- [253] M. Dembo, On peeling an adherent cell from a surface, *Lectures on Mathematics in the life sciences* 24 (1994) 51–77.
- [254] C.E. Orsello, D.A. Lauffenburger, D.A. Hammer, Molecular properties in cell adhesion: a physical and engineering perspective, *TRENDS in Biotechnology* 19 (8) (2001) 310–316.
- [255] J. Hubble, Monte Carlo simulation of biospecific interactions between cells and surfaces, *Chemical engineering science* 58 (19) (2003) 4465–4474.
- [256] N. N'dri, W. Shyy, R. Tran-Son-Tay, Computational modeling of cell adhesion and movement using a continuum-kinetics approach, *Biophysical journal* 85 (4) (2003) 2273–2286.
- [257] J. Hubble, Affinity adsorption of cells to surfaces and strategies for cell detachment, *Cell Separation* (2007) 75–99.
- [258] A. Lam, X. Cao, R. Eisinger, J. Hubble, Effect of contact time and inhibitor concentration on the affinity mediated adsorption of cells to surfaces, *Enzyme and microbial technology* 29 (1) (2001) 28–33.
- [259] D.B. Khismatullin, G.A. Truskey, A 3D numerical study of the effect of channel height on leukocyte deformation and adhesion in parallel-plate flow chambers, *Microvascular research* 68 (3) (2004) 188–202.
- [260] D.B. Khismatullin, G.A. Truskey, Three-dimensional numerical simulation of receptor-mediated leukocyte adhesion to surfaces: Effects of cell deformability and viscoelasticity, *Physics of Fluids* 17 (3) (2005) 031505.
- [261] S.K. Murthy, A. Sin, R.G. Tompkins, M. Toner, Effect of flow and surface conditions on human lymphocyte isolation using microfluidic chambers, *Langmuir* 20 (26) (2004) 11649–11655.
- [262] W.C. Chang, L.P. Lee, D. Liepmann, Biomimetic technique for adhesion-based collection and separation of cells in a microfluidic channel, *Lab on a Chip* 5 (1) (2005) 64–73.
- [263] A.W. Greenberg, D.A. Hammer, Cell separation mediated by differential rolling adhesion, *Biotechnology and bioengineering* 73 (2) (2001) 111–124.
- [264] R. Karnik, S. Hong, H. Zhang, Y. Mei, D.G. Anderson, J.M. Karp, R. Langer, Nanomechanical control of cell rolling in two dimensions through surface patterning of receptors, *Nano letters* 8 (4) (2008) 1153–1158.
- [265] D.A. Hammer, S.M. Apte, Simulation of cell rolling and adhesion on surfaces in shear flow: general results and analysis of selectin-mediated neutrophil adhesion, *Biophysical journal* 63 (1) (1992) 35–57.
- [266] K.-C. Chang, D.F. Tees, D.A. Hammer, The state diagram for cell adhesion under flow: leukocyte rolling and firm adhesion, *Proceedings of the National Academy of Sciences* 97 (21) (2000) 11262–11267.
- [267] C. Dong, X.X. Lei, Biomechanics of cell rolling: shear flow, cell-surface adhesion, and cell deformability, *Journal of biomechanics* 33 (1) (2000) 35–43.
- [268] M.R. King, D.A. Hammer, Multiparticle adhesive dynamics. Interactions between stably rolling cells, *Biophysical journal* 81 (2) (2001) 799–813.
- [269] B. Mattiasson, *Expanded bed chromatography*, Springer Science & Business Media, 2013.
- [270] L. Ujam, R. Clemmitt, H. Chase, Cell separation by expanded bed adsorption: use of ion exchange chromatography for the separation of *E. coli* and *S. cerevisiae*, *Bioprocess and Biosystems Engineering* 23 (3) (2000) 245–250.
- [271] R. Clemmitt, H. Chase, Impact of operating variables on the expanded bed adsorption of *Saccharomyces cerevisiae* cells using a concanavalin A derivatized perfluorocarbon, *Biotechnology and bioengineering* 82 (5) (2003) 506–516.
- [272] L. Ujam, R. Clemmitt, S. Clarke, R. Brooks, N. Rushton, H. Chase, Isolation of monocytes from human peripheral blood using immuno-affinity expanded-bed adsorption, *Biotechnology and bioengineering* 83 (5) (2003) 554–566.
- [273] G.E. McCreath, H.A. Chase, Affinity adsorption of *Saccharomyces cerevisiae* on concanavalin A perfluorocarbon emulsions, *Journal of Molecular Recognition* 9 (5–6) (1996) 607–616.
- [274] D.Q. Lin, M.R. Kula, A. Liten, J. Thömmes, Stability of expanded beds during the application of crude feedstock, *Biotechnology and bioengineering* 81 (1) (2003) 21–26.
- [275] F.M. Plieva, I.Y. Galaev, W. Noppe, B. Mattiasson, Cryogel applications in microbiology, *Trends in microbiology* 16 (11) (2008) 543–551.
- [276] M.B. Dainiak, A. Kumar, I.Y. Galaev, B. Mattiasson, Cryogels as matrices for cell separation and cell cultivation, *Macroporous Polymers: Production Properties and Biotechnological/Biomaterial Applications* (2009) 363.
- [277] N.K. Singh, R.N. Dsouza, M. Grasselli, M. Fernández-Lahore, High capacity cryogel-type adsorbents for protein purification, *Journal of Chromatography A* 1355 (2014) 143–148.
- [278] M. Emin Çorman, N. Bereli, S. Özkara, L. Uzun, A. Denizli, Hydrophobic cryogels for DNA adsorption: Effect of embedding of monosize microbeads into cryogel network on their adsorptive performances, *Biomedical Chromatography* 27 (11) (2013) 1524–1531.
- [279] D. Çimen, F. Yılmaz, I. Perçin, D. Türkmen, A. Denizli, Dye affinity cryogels for plasmid DNA purification, *Materials Science and Engineering: C* 56 (2015) 318–324.
- [280] S.L. Williams, M.E. Eccleston, N.K. Slater, Affinity capture of a biotinylated retrovirus on macroporous monolithic adsorbents: Towards a rapid single-step purification process, *Biotechnology and bioengineering* 89 (7) (2005) 783–787.
- [281] V.I. Lozinsky, I.Y. Galaev, F.M. Plieva, I.N. Savina, H. Jungvid, B. Mattiasson, Polymeric cryogels as promising materials of biotechnological interest, *TRENDS in Biotechnology* 21 (10) (2003) 445–451.
- [282] A. Jungbauer, R. Hahn, Polymethacrylate monoliths for preparative and industrial separation of biomolecular assemblies, *Journal of chromatography A* 1184 (1) (2008) 62–79.
- [283] R.D. Arrua, C.I. Alvarez Igarzabal, Macroporous monolithic supports for affinity chromatography, *J. Sep. Sci.* 34 (16–17) (2011) 1974–1987.
- [284] E. Jain, A. Kumar, Disposable polymeric cryogel bioreactor matrix for therapeutic protein production, *Nature protocols* 8 (5) (2013) 821–835.
- [285] A. Kumar, A. Bhardwaj, Methods in cell separation for biomedical application: cryogels as a new tool, *Biomedical materials* 3 (3) (2008) 034008.
- [286] M.B. Dainiak, I.Y. Galaev, B. Mattiasson, Affinity cryogel monoliths for screening for optimal separation conditions and chromatographic separation of cells, *Journal of Chromatography A* 1123 (2) (2006) 145–150.
- [287] A. Podgornik, N.L. Krajnc, Application of monoliths for bioparticle isolation, *J. Sep. Sci.* 35 (22) (2012) 3059–3072.
- [288] V.I. Lozinsky, F.M. Plieva, I.Y. Galaev, B. Mattiasson, The potential of polymeric cryogels in bioseparation, *Bioseparation* 10 (4) (2001) 163–188.
- [289] M.B. Dainiak, A. Kumar, I.Y. Galaev, B. Mattiasson, Detachment of affinity-captured bioparticles by elastic deformation of a macroporous hydrogel, *Proceedings of the National Academy of Sciences of the United States of America* 103 (4) (2006) 849–854.
- [290] S. Ott, R. Niessner, M. Seidel, Preparation of epoxy-based macroporous monolithic columns for the fast and efficient immunofiltration of *Staphylococcus aureus*, *Journal of separation science* 34 (16–17) (2011) 2181–2192.
- [291] I.Y. Galaev, M.B. Dainiak, F. Plieva, B. Mattiasson, Effect of matrix elasticity on affinity binding and release of bioparticles. Elution of bound cells by temperature-induced shrinkage of the smart macroporous hydrogel, *Langmuir* 23 (1) (2007) 35–40.
- [292] P. Arvidsson, F.M. Plieva, I.N. Savina, V.I. Lozinsky, S. Fexby, L. Bülow, I.Y. Galaev, B. Mattiasson, Chromatography of microbial cells using continuous supermacroporous affinity and ion-exchange columns, *Journal of Chromatography A* 977 (1) (2002) 27–38.
- [293] M.B. Dainiak, F.M. Plieva, I.Y. Galaev, R. Hatti-Kaul, B. Mattiasson, Cell chromatography: Separation of different microbial cells using IMAC supermacroporous monolithic columns, *Biotechnology progress* 21 (2) (2005) 644–649.
- [294] A. Srivastava, A.K. Shukla, A. Kumar, Boronate affinity chromatography of cells and biomacromolecules using cryogel matrices, *Enzyme and microbial technology* 51 (6) (2012) 373–381.
- [295] A. Srivastava, S. Singh, A. Kumar, 16 Supermacroporous Functional Cryogel Stationary Matrices for Efficient Cell Separation, *Supermacroporous Cryogels: Biomedical and Biotechnological Applications* (2016) 445.
- [296] F.M. Plieva, I.N. Savina, S. Deraz, J. Andersson, I.Y. Galaev, B. Mattiasson, Characterization of supermacroporous monolithic polyacrylamide based matrices designed for chromatography of bioparticles, *Journal of Chromatography B* 807 (1) (2004) 129–137.
- [297] M. Szczesna-Antczak, E. Galas, *Bacillus subtilis* cells immobilised in PVA-cryogels, *Biomolecular Engineering* 17 (2) (2001) 55–63.
- [298] E.F. Gold, R. Kleinman, S. Ben-Efraim, A heat-digestible cell-immunoabsorbent made by coupling hapten to gelatin, *Journal of immunological methods* 6 (1–2) (1974) 31–37.
- [299] E. Kedar, M.O. de Landazuri, B. Bonavida, Cellular immunoabsorbents: a simplified technique for separation of lymphoid cell populations, *The Journal of Immunology* 112 (3) (1974) 1231–1243.
- [300] W. Haas, Separation of antigen-specific lymphocytes. II. Enrichment of hapten-specific antibody-forming cell precursors, *Journal of Experimental Medicine* 141 (5) (1975) 1015–1029.
- [301] W. Haas, J.E. Layton, Separation of antigen-specific lymphocytes. I. Enrichment of antigen-binding cells, *Journal of Experimental Medicine* 141 (5) (1975) 1004–1014.
- [302] C. Webb, D. Teitelbaum, H. Rauch, A. Maoz, R. Arnon, S. Fuchs, Fractionation of functional lymphocytes sensitized to basic encephalitogen on derivatized collagen and gelatin gels, *The Journal of Immunology* 114 (5) (1975) 1469–1472.
- [303] A. Maoz, G. Shellam, Fractionation of cytotoxic cells from tumour-immune rats on derivatized collagen gels, *Journal of immunological methods* 12 (1–2) (1976) 125–130.
- [304] E.B. Bröcker, C. Sorg, Specific separation of cytotoxic T lymphocytes on immunoabsorptive films, *Journal of immunological methods* 14 (3–4) (1977) 333–342.
- [305] G. Nossal, B.L. Pike, Improved procedures for the fractionation and in vitro stimulation of hapten-specific B lymphocytes, *The Journal of Immunology* 120 (1) (1978) 145–150.
- [306] G. Edelman, U. Rutishauser, C. Millette, Cell fractionation and arrangement on fibers, beads, and surfaces, *Proceedings of the National Academy of Sciences* 68 (9) (1971) 2153–2157.
- [307] R.E. Nordon, D.N. Haylock, L. Gaudry, K. Schindhelm, Hollow-fibre affinity cell separation system for CD34+ cell enrichment, *Cytometry* 24 (4) (1996) 340–347.

- [308] R.E. Nordon, K. Schindhelm, Design of hollow fiber modules for uniform shear elution affinity cell separation, *Artificial organs* 21 (2) (1997) 107–115.
- [309] C. Orsello, D. Lauffenburger, C. Colton, Characterization of cell detachment from hollow fiber affinity membranes, *Biomedical sciences instrumentation* 35 (1998) 315–320.
- [310] R.E. Nordon, A. Shu, F. Camacho, B.K. Milthorpe, Hollow-fiber assay for ligand-mediated cell adhesion, *Cytometry Part A* 57 (1) (2004) 39–44.
- [311] S.J. Craig, A. Shu, Y. Xu, F.C. Foong, R. Nordon, Chimeric protein for selective cell attachment onto cellulosic substrates, *Protein Engineering, Design & Selection* 20 (5) (2007) 235–241.
- [312] R. Nordon, S. Craig, Hollow-fibre affinity cell separation, *Cell Separation* (2007) 129–150.
- [313] G. Xu, Y. Tan, T. Xu, D. Yin, M. Wang, M. Shen, X. Chen, X. Shi, X. Zhu, Hyaluronic acid-functionalized electrospun PLGA nanofibers embedded in a microfluidic chip for cancer cell capture and culture, *Biomaterials science* 5 (4) (2017) 752–761.
- [314] N.M. Pope, D.L. Kulcinski, A. Hardwick, Y.A. Chang, New application of silane coupling agents for covalently binding antibodies to glass and cellulose solid supports, *Bioconjugate chemistry* 4 (2) (1993) 166–171.
- [315] R. Saranya, R. Murugan, M. Hegde, J. Doyle, R. Babu, Affinity membranes for capture of cells and biological substances, *Filtering Media by Electrospinning*, Springer, 2018, pp. 175–195.
- [316] E. Mandrusov, A. Houg, E. Klein, E.F. Leonard, Membrane-based cell affinity chromatography to retrieve viable cells, *Biotechnology progress* 11 (2) (1995) 208–213.
- [317] S. Barkley, H. Johnson, R. Eienthal, J. Hubble, Bubble-induced detachment of affinity-adsorbed erythrocytes, *Biotechnology and applied biochemistry* 40 (2) (2004) 145–149.
- [318] A. Okamura, M. Itayagoshi, T. Hagiwara, M. Yamaguchi, T. Kanamori, T. Shinbo, P.-C. Wang, Poly (N-isopropylacrylamide)-graft-polypropylene membranes containing adsorbed antibody for cell separation, *Biomaterials* 26 (11) (2005) 1287–1292.
- [319] A. Okamura, T. Hagiwara, S. Yamagami, M. Yamaguchi, T. Shinbo, T. Kanamori, S. Kondo, K. Miwa, I. Itagaki, Effective cell separation utilizing poly (N-isopropylacrylamide)-grafted polypropylene membrane containing adsorbed antibody, *Journal of bioscience and bioengineering* 105 (3) (2008) 221–225.
- [320] P.-A. Albertsson, Separation of cell organelles and membrane vesicles by phase partition, *Progress in clinical and biological research* 270 (1988) 227.
- [321] L.J. Karr, J.M. Van Alstine, R.S. Snyder, S.G. Shafer, J.M. Harris, Cell separation by immunoaffinity partitioning with polyethylene glycol-modified protein A in aqueous polymer two-phase systems, *Journal of Chromatography A* 442 (1988) 219–227.
- [322] C. Delgado, R.J. Anderson, G.E. Francis, D. Fisher, Separation of cell mixtures by immunoaffinity cell partitioning: strategies for low abundance cells, *Analytical biochemistry* 192 (2) (1991) 322–328.
- [323] C. Delgado, P. Sancho, J. Medieta, J. Luque, Ligand-receptor interactions in affinity cell partitioning: studies with transferrin covalently linked to monomethoxypoly (ethylene glycol) and rat reticulocytes, *Journal of Chromatography A* 594 (1–2) (1992) 97–103.
- [324] P.A. Rosa, A.M. Azevedo, M.R. Aires-Barros, Application of central composite design to the optimisation of aqueous two-phase extraction of human antibodies, *Journal of Chromatography A* 1141 (1) (2007) 50–60.
- [325] A.F. Sousa, P.Z. Andrade, R.M. Pirzagska, T.M. Galhoz, A.M. Azevedo, C.L. Da Silva, M. Raquel Aires-Barros, J.M. Cabral, A novel method for human hematopoietic stem/progenitor cell isolation from umbilical cord blood based on immunoaffinity aqueous two-phase partitioning, *Biotechnology letters* 33 (12) (2011) 2373–2377.
- [326] M. González-González, M. Rito-Palomares, Aqueous two-phase systems strategies to establish novel bioprocesses for stem cells recovery, *Critical reviews in biotechnology* 34 (4) (2014) 318–327.
- [327] M. González-González, M. Rito-Palomares, O. Méndez Quintero, Partition behavior of CD133+ stem cells from human umbilical cord blood in aqueous two-phase systems: In route to establish novel stem cell primary recovery strategies, *Biotechnology progress* 30 (3) (2014) 700–707.
- [328] M. González-González, M. Rito-Palomares, Application of affinity aqueous two-phase systems for the fractionation of CD133+ stem cells from human umbilical cord blood, *Journal of Molecular Recognition* 28 (3) (2015) 142–147.
- [329] M. González-González, R.C. Willson, M. Rito-Palomares, Elimination of contaminants from cell preparations using aqueous two-phase partitioning, *Separation and Purification Technology* 158 (2016) 103–107.
- [330] S. Brandt, R. Goffe, S. Kessler, J. O'Connor, S. Zale, E. Klein, Affinity Partitioning in Aqueous Two-Phase Systems, (2000).
- [331] A. Kumar, M. Kamihira, B. Mattiasson, Two-phase affinity partitioning of animal cells: implications of multipoint interactions, *Methods for affinity-based separations of enzymes and proteins* (2002) 163–180.
- [332] R. Hamamoto, M. Kamihira, S. Iijima, Specific separation of animal cells using aqueous two-phase systems, *Journal of fermentation and bioengineering* 82 (1) (1996) 73–76.
- [333] E. Laboureaud, J. Capiod, C. Dessaint, L. Prin, M. Vijayalakshmi, Study of human cord blood lymphocytes by immobilized metal ion affinity partitioning, *Journal of Chromatography B: Biomedical Sciences and Applications* 680 (1) (1996) 189–195.
- [334] J. Cabral, Cell partitioning in aqueous two-phase polymer systems, *Cell separation* (2007) 151–171.
- [335] L.J. Karr, S.G. Shafer, J.M. Harris, J.M. Van Alstine, R.S. Snyder, Immuno-affinity partition of cells in aqueous polymer two-phase systems, *Journal of Chromatography A* 354 (1986) 269–282.
- [336] K.A. Sharp, M. Yalpani, S.J. Howard, D.E. Brooks, Synthesis and application of a poly (ethylene glycol)-antibody affinity ligand for cell separations in aqueous polymer two-phase systems, *Analytical biochemistry* 154 (1) (1986) 110–117.
- [337] A. Kumar, M. Kamihira, I.Y. Galaev, B. Mattiasson, S. Iijima, Type-specific separation of animal cells in aqueous two-phase systems using antibody conjugates with temperature-sensitive polymers, *Biotechnology and bioengineering* 75 (5) (2001) 570–580.
- [338] B.M. Muñio, P.J. Cebrian, B. Olde, G. Johansson, Effect of dextran-and poly (ethylene glycol)-bound procion yellow HE-3G on the partition of membranes from calf brain synaptosomes within an aqueous two-phase system, *Journal of chromatography* 358 (1) (1986) 147–158.
- [339] M.T.M. Blanco, J.A. Cebrian, B. Olde, G. Johansson, Subfractions of membranes from calf brain synaptosomes obtained and studied by liquid–liquid partitioning, *Journal of Chromatography A* 547 (1991) 79–87.
- [340] J.C. Pérez, M.T.M. Blanco, G. Johansson, Heterogeneity of synaptosomal membrane preparations from different regions of calf brain studied by partitioning and counter-current distribution, *International journal of biochemistry* 23 (12) (1991) 1491–1495.
- [341] G. Zijlstra, M. Michielsen, C. De Gooijer, L. Van der Pol, J. Tramper, Separation of hybridoma cells from their IgG product using aqueous two-phase systems, *Bioseparation* 6 (4) (1995) 201–210.
- [342] G. Zijlstra, M. Michielsen, C. De Gooijer, L. Van der Pol, J. Tramper, IgG and hybridoma partitioning in aqueous two-phase systems containing a dye-ligand, *Bioseparation* 7 (2) (1998) 117–126.
- [343] E. Nanak, M. Vijayalakshmi, K. Chadha, Segregation of normal and pathological human red blood cells, lymphocytes and fibroblasts by immobilized metal-ion affinity partitioning, *Journal of Molecular Recognition* 8 (1–2) (1995) 77–84.
- [344] J. Ugelstad, A. Berge, T. Ellingsen, O. Aune, L. Kilaas, T. Nilsen, R. Schmid, P. Stenstad, S. Funderud, G. Kvalheim, Monosized magnetic particles and their use in selective cell separation, *Macromolecular Symposia*, Wiley Online Library (1988) 177–211.
- [345] B. Schmitz, A. Radbruch, T. Kümmel, C. Wickenhauser, H. Korb, M. Hansmann, J. Thiele, R. Fischer, Magnetic activated cell sorting (MACS)—a new immunomagnetic method for megakaryocytic cell isolation: comparison of different separation techniques, *European journal of haematology* 52 (5) (1994) 267–275.
- [346] M. Zborowski, C.B. Fuh, R. Green, L. Sun, J.J. Chalmers, Analytical magnetapheresis of ferritin-labeled lymphocytes, *Analytical chemistry* 67 (20) (1995) 3702–3712.
- [347] L. Sun, M. Zborowski, L.R. Moore, J.J. Chalmers, Continuous, flow-through immunomagnetic cell sorting in a quadrupole field, *Cytometry Part A* 33 (4) (1998) 469–475.
- [348] J.J. Chalmers, Y. Zhao, M. Nakamura, K. Melnik, L. Lasky, L. Moore, M. Zborowski, An instrument to determine the magnetophoretic mobility of labeled, biological cells and paramagnetic particles, *Journal of Magnetism and Magnetic Materials* 194 (1) (1999) 231–241.
- [349] K.E. McCloskey, J.J. Chalmers, M. Zborowski, Magnetophoretic mobilities correlate to antibody binding capacities, *Cytometry Part A* 40 (4) (2000) 307–315.
- [350] K.E. McCloskey, J.J. Chalmers, M. Zborowski, Magnetic cell separation: characterization of magnetophoretic mobility, *Analytical chemistry* 75 (24) (2003) 6868–6874.
- [351] J.J. Chalmers, M. Zborowski, L. Sun, L. Moore, Flow through, immunomagnetic cell separation, *Biotechnology progress* 14 (1) (1998) 141–148.
- [352] J.D. Adams, U. Kim, H.T. Soh, Multitarget magnetic activated cell sorter, *Proceedings of the National Academy of Sciences* 105(47) (2008) 18165–18170.
- [353] N.-T. Huang, Y.-J. Hwang, R.L. Lai, A microfluidic microwell device for immunomagnetic single-cell trapping, *Microfluidics and Nanofluidics* 22 (2) (2018) 16.
- [354] D. Islam, A. Lindberg, Detection of Shigella dysenteriae type 1 and Shigella flexneri in feces by immunomagnetic isolation and polymerase chain reaction, *Journal of clinical microbiology* 30 (11) (1992) 2801–2806.
- [355] C. Evaristo, P. Steinbrück, J. Pankratz, Z. Yu, C. Dose, REAlease™ Immunomagnetic Separation Technology with reversible labeling for positive selection of leukocytes, *Am Assoc Immunol* (2018).
- [356] G.H. Mazurek, V. Reddy, D. Murphy, T. Ansari, Detection of Mycobacterium tuberculosis in cerebrospinal fluid following immunomagnetic enrichment, *Journal of clinical microbiology* 34 (2) (1996) 450–453.
- [357] X. Zhou, B. Luo, K. Kang, S. Ma, X. Sun, F. Lan, Q. Yi, Y. Wu, Multifunctional luminescent immuno-magnetic nanoparticles: toward fast, efficient, cell-friendly capture and recovery of circulating tumor cells, *Journal of Materials Chemistry B* 7 (3) (2019) 393–400.
- [358] M.Q. Deng, D.O. Cliver, T.W. Mariani, Immunomagnetic capture PCR to detect viable Cryptosporidium parvum oocysts from environmental samples, *Applied and environmental microbiology* 63 (8) (1997) 3134–3138.
- [359] L. Rao, Q.F. Meng, Q. Huang, Z. Wang, G.T. Yu, A. Li, W. Ma, N. Zhang, S.S. Guo, X.Z. Zhao, Platelet-Leukocyte Hybrid Membrane-Coated Immunomagnetic Beads for Highly Efficient and Highly Specific Isolation of Circulating Tumor Cells, *Advanced Functional Materials* 28 (34) (2018) 1803531.
- [360] M. Shinkai, M. Suzuki, S. Iijima, T. Kobayashi, Antibody-conjugated magnetoliposomes for targeting cancer cells and their application in hyperthermia, *Biotechnology and applied biochemistry* 21 (2) (1995) 125–137.
- [361] V.L. Dhadge, A. Hussain, A.M. Azevedo, R. Aires-Barros, A.C. Roque, Boronic

- acid-modified magnetic materials for antibody purification, *Journal of The Royal Society Interface* 11 (91) (2014) 20130875.
- [362] W.H. Scouten, P. Konecny, Reversible immobilization of antibodies on magnetic beads, *Analytical biochemistry* 205 (2) (1992) 313–318.
- [363] A. Benez, A. Geiselhart, R. Handgretinger, U. Schiebel, G. Fierlbeck, Detection of circulating melanoma cells by immunomagnetic cell sorting, *Journal of clinical laboratory analysis* 13 (5) (1999) 229–233.
- [364] S. Grunewald, U. Paasch, H.-J. Glander, Enrichment of non-apoptotic human spermatozoa after cryopreservation by immunomagnetic cell sorting, *Cell and tissue banking* 2 (3) (2001) 127–133.
- [365] N. Pimpha, S. Chaleawler-umpon, N. Chruewkamlow, W. Kasinrer, Preparation of anti-CD4 monoclonal antibody-conjugated magnetic poly (glycidyl methacrylate) particles and their application on CD4+ lymphocyte separation, *Talanta* 84 (1) (2011) 89–97.
- [366] C. Jackson, P. Garbett, B. Nissen, L. Schrieber, Binding of human endothelium to Ulex europaeus I-coated Dynabeads: application to the isolation of microvascular endothelium, *Journal of cell science* 96 (2) (1990) 257–262.
- [367] P.D. Rye, Sweet and sticky: carbohydrate-coated magnetic beads, *Nature Biotechnology* 14 (2) (1996) 155–157.
- [368] L.J.-S. Yang, C.B. Zeller, R.L. Schnaar, Detection and isolation of lectin-transfected COS cells based on cell adhesion to immobilized glycosphingolipids, *Analytical biochemistry* 236 (1) (1996) 161–167.
- [369] P.D. Rye, N.V. Bovin, Selection of carbohydrate-binding cell phenotypes using oligosaccharide-coated magnetic particles, *Glycobiology* 7 (2) (1997) 179–182.
- [370] B.E. Collins, L. Yang, R.L. Schnaar, Lectin-mediated cell adhesion to immobilized glycosphingolipids, *Methods in enzymology* 312 (1999) 438–446.
- [371] J.K. Herr, J.E. Smith, C.D. Medley, D. Shangguan, W. Tan, Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells, *Analytical Chemistry* 78 (9) (2006) 2918–2924.
- [372] J.E. Smith, C.D. Medley, Z. Tang, D. Shangguan, C. Lofton, W. Tan, Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells, *Analytical Chemistry* 79 (8) (2007) 3075–3082.
- [373] Z. Tang, D. Shangguan, K. Wang, H. Shi, K. Sefah, P. Mallikratchy, H.W. Chen, Y. Li, W. Tan, Selection of aptamers for molecular recognition and characterization of cancer cells, *Analytical chemistry* 79 (13) (2007) 4900–4907.
- [374] X. Dong, Y. Zheng, Y. Huang, X. Chen, X. Jing, Synthesis and characterization of multifunctional poly (glycidyl methacrylate) microspheres and their use in cell separation, *Analytical biochemistry* 405 (2) (2010) 207–212.
- [375] J.-J. Lee, K.J. Jeong, M. Hashimoto, A.H. Kwon, A. Rwei, S.A. Shankarappa, J.H. Tsui, D.S. Kohane, Synthetic ligand-coated magnetic nanoparticles for microfluidic bacterial separation from blood, *Nano letters* 14 (1) (2013) 1–5.
- [376] S. Riethdorf, H. Fritsche, V. Müller, T. Rau, C. Schindlbeck, B. Rack, W. Janni, C. Coith, K. Beck, F. Jänicke, Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system, *Clinical cancer research* 13 (3) (2007) 920–928.
- [377] D.L. Adams, S. Stefansson, C. Haudenschild, S.S. Martin, M. Charpentier, S. Chumsri, M. Cristofanilli, C.M. Tang, R.K. Alpaugh, Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the cellsearch® CTC test, *Cytometry Part A* 87 (2) (2015) 137–144.
- [378] N. Beijer, A. Jager, S. Sleijfer, Circulating tumor cell enumeration by the CellSearch system: the clinician's guide to breast cancer treatment? *Cancer treatment reviews* 41 (2) (2015) 144–150.
- [379] L.A. Herzenberg, D. Parks, B. Sahaf, O. Perez, M. Roederer, L.A. HERZENBERG, The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford, *Clinical chemistry* 48 (10) (2002) 1819–1827.
- [380] M. González-González, P. Vázquez-Villegas, C. García-Salinas, M. Rito-Palmares, Current strategies and challenges for the purification of stem cells, *Journal of Chemical Technology and Biotechnology* 87 (1) (2012) 2–10.
- [381] L. Liu, T.H. Cheung, G.W. Charville, T.A. Rando, Isolation of skeletal muscle stem cells by fluorescence-activated cell sorting, *Nature protocols* 10 (10) (2015) 1612–1624.
- [382] J. Pruszk, K.C. Sonntag, M.H. Aung, R. Sanchez-Pernaute, O. Isacson, Markers and methods for cell sorting of human embryonic stem cell-derived neural cell populations, *Stem cells* 25 (9) (2007) 2257–2268.
- [383] C.Y. Fong, G.S. Peh, K. Gauthaman, A. Bongso, Separation of SSEA-4 and TRA-1–60 labelled undifferentiated human embryonic stem cells from a heterogeneous cell population using magnetic-activated cell sorting (MACS) and fluorescence-activated cell sorting (FACS), *Stem Cell Reviews and Reports* 5 (1) (2009) 72–80.
- [384] D.-C. Lee, Y.-C. Hsu, Y.-F. Chung, C.-Y. Hsiao, S.-L. Chen, M.-S. Chen, H.-K. Lin, M. Chiu, Isolation of neural stem/progenitor cells by using EGF/FGF1 and FGF1B promoter-driven green fluorescence from embryonic and adult mouse brains, *Molecular and Cellular Neuroscience* 41 (3) (2009) 348–363.
- [385] I.L. Weissman, J.A. Shizuru, The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases, *Blood* 112 (9) (2008) 3543–3553.
- [386] Y. Chen, A.J. Chung, T.H. Wu, M.A. Teitell, D. Di Carlo, P.Y. Chiou, Pulsed laser activated cell sorting with three dimensional sheathless inertial focusing, *Small* 10 (9) (2014) 1746–1751.
- [387] A.A.S. Bhagat, H. Bow, H.W. Hou, S.J. Tan, J. Han, C.T. Lim, Microfluidics for cell separation, *Medical and Biological Engineering and Computing* 48 (10) (2010) 999–1014.
- [388] S.C. De Rosa, L.A. Herzenberg, L.A. Herzenberg, M. Roederer, 13-color, 13-parameter flow cytometry: identification of human naive T cells by phenotype, function, and T-cell receptor diversity, *Nature medicine* 7 (2) (2001) 245–248.
- [389] S.P. Perfetto, P.K. Chattopadhyay, M. Roederer, Seventeen-colour flow cytometry: unravelling the immune system, *Nature Reviews Immunology* 4 (8) (2004) 648–655.
- [390] C. Murray, E. Pao, P. Tseng, S. Aftab, R. Kulkarni, M. Rettig, D. Di Carlo, Quantitative magnetic separation of particles and cells using gradient magnetic ratcheting, *Small* 12 (14) (2016) 1891–1899.
- [391] C. Murray, E. Pao, A. Jann, D.E. Park, D. Di Carlo, Continuous and Quantitative Purification of T-Cell Subsets for Cell Therapy Manufacturing Using Magnetic Ratcheting Cytometry, *SLAS TECHNOLOGY: Translating Life Sciences Innovation* 23 (4) (2018) 326–337.
- [392] P. Li, Y. Tian, D. Pappas, Comparison of inlet geometry in microfluidic cell affinity chromatography, *Analytical chemistry* 83 (3) (2011) 774–781.
- [393] J. Chen, J. Li, Y. Sun, Microfluidic approaches for cancer cell detection, characterization, and separation, *Lab on a Chip* 12 (10) (2012) 1753–1767.
- [394] Y. Gao, W. Li, Y. Zhang, D. Pappas, Cell Affinity Separations on Microfluidic Devices, *Affinity Chromatography: Methods and Protocols* (2015) 55–65.
- [395] Y. Zhang, W. Li, Y. Zhou, A. Johnson, A. Venable, A. Hassan, J. Griswold, D. Pappas, Detection of sepsis in patient blood samples using CD64 expression in a microfluidic cell separation device, *Analyst* 143 (1) (2018) 241–249.
- [396] M. Zhang, B. Xu, A. Siehr, W. Shen, Efficient release of immunocaptured cells using coiled-coils in a microfluidic device, *RSC Advances* 9 (50) (2019) 29182–29189.
- [397] S. Nagrath, L.V. Sequist, S. Maheswaran, D.W. Bell, D. Irimia, L. Ulkus, M.R. Smith, E.L. Kwak, S. Digumarthy, A. Muzikansky, Isolation of rare circulating tumour cells in cancer patients by microchip technology, *Nature* 450 (7173) (2007) 1235–1239.
- [398] J.P. Gleghorn, E.D. Pratt, D. Denning, H. Liu, N.H. Bander, S.T. Tagawa, D.M. Nanus, P.A. Giannakakou, B.J. Kirby, Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody, *Lab on a chip* 10 (1) (2010) 27–29.
- [399] S.K. Arya, B. Lim, A.R.A. Rahman, Enrichment, detection and clinical significance of circulating tumor cells, *Lab on a Chip* 13 (11) (2013) 1995–2027.
- [400] X. Cheng, D. Irimia, M. Dixon, K. Sekine, U. Demirci, L. Zamir, R.G. Tompkins, W. Rodriguez, M. Toner, A microfluidic device for practical label-free CD4+ T cell counting of HIV-infected subjects, *Lab on a Chip* 7 (2) (2007) 170–178.
- [401] A. Hatch, G. Hansmann, S.K. Murthy, Engineered alginate hydrogels for effective microfluidic capture and release of endothelial progenitor cells from whole blood, *Langmuir* 27 (7) (2011) 4257–4264.
- [402] A.M. Shah, M. Yu, Z. Nakamura, J. Ciciliano, M. Ulman, K. Kotz, S.L. Stott, S. Maheswaran, D.A. Haber, M. Toner, Biopolymer system for cell recovery from microfluidic cell capture devices, *Analytical chemistry* 84 (8) (2012) 3682–3688.
- [403] J.A. Phillips, Y. Xu, Z. Xia, Z.H. Fan, W. Tan, Enrichment of cancer cells using aptamers immobilized on a microfluidic channel, *Analytical chemistry* 81 (3) (2008) 1033–1039.
- [404] E.D. Pratt, C. Huang, B.G. Hawkins, J.P. Gleghorn, B.J. Kirby, Rare cell capture in microfluidic devices, *Chemical engineering science* 66 (7) (2011) 1508–1522.
- [405] M. Yu, S. Stott, M. Toner, S. Maheswaran, D.A. Haber, Circulating tumor cells: approaches to isolation and characterization, *The Journal of cell biology* 192 (3) (2011) 373–382.
- [406] S.L. Stott, C.-H. Hsu, D.I. Tsukrov, M. Yu, D.T. Miyamoto, B.A. Waltman, S.M. Rothenberg, A.M. Shah, M.E. Smas, G.K. Korir, Isolation of circulating tumor cells using a microvortex-generating herringbone-chip, *Proceedings of the National Academy of Sciences* 107 (43) (2010) 18392–18397.
- [407] A. Ciurte, C. Selicean, O. Soritau, R. Buiga, Automatic detection of circulating tumor cells in darkfield microscopic images of unstained blood using boosting techniques, *PLoS one* 13 (12) (2018).
- [408] Z. Shen, A. Wu, X. Chen, Current detection technologies for circulating tumor cells, *Chemical Society Reviews* 46 (8) (2017) 2038–2056.
- [409] J.H. Myung, K.A. Gajjar, J. Saric, D.T. Eddington, S. Hong, Dendrimer-Mediated Multivalent Binding for the Enhanced Capture of Tumor Cells, *Angewandte Chemie International Edition* 50 (49) (2011) 11769–11772.
- [410] H. Esmailsabzali, T.V. Beischlag, M.E. Cox, A.M. Parameswaran, E.J. Park, Detection and isolation of circulating tumor cells: principles and methods, *Biotechnology advances* 31 (7) (2013) 1063–1084.
- [411] M. Lustberg, K.R. Jatana, M. Zborowski, J.J. Chalmers, Emerging technologies for CTC detection based on depletion of normal cells, *Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer*, Springer 2012, pp. 97–110.
- [412] A. Toss, Z. Mu, S. Fernandez, M. Cristofanilli, CTC enumeration and characterization: moving toward personalized medicine, *Annals of translational medicine* 2 (11) (2014).
- [413] H. Kang, J. Kim, H. Cho, K.-H. Han, Evaluation of Positive and Negative Methods for Isolation of Circulating Tumor Cells by Lateral Magnetophoresis, *Micromachines* 10 (6) (2019) 386.
- [414] X. Wang, L. Sun, H. Zhang, L. Wei, W. Qu, Z. Zeng, Y. Liu, Z. Zhu, Microfluidic chip combined with magnetic-activated cell sorting technology for tumor antigen-independent sorting of circulating hepatocellular carcinoma cells, *PeerJ* 7 (2019) e6681.
- [415] E. Mereu, A. Lafzi, C. Moutinho, C. Ziegenhain, D.J. McCarthy, A. Álvarez-Varela, E. Batlle, D. Grün, J.K. Lau, S.C. Boutet, Benchmarking single-cell RNA-sequencing protocols for cell atlas projects, *Nature Biotechnology* (2020) 1–9.
- [416] H.M. Kang, M. Subramaniam, S. Targ, M. Nguyen, L. Maliskova, E. McCarthy, E. Wan, S. Wong, L. Byrnes, C.M. Lanata, Multiplexed droplet single-cell

- RNA-sequencing using natural genetic variation, *Nature biotechnology* 36 (1) (2018) 89.
- [417] R. Zilionis, J. Nainys, A. Veres, V. Savova, D. Zemmour, A.M. Klein, L. Mazutis, Single-cell barcoding and sequencing using droplet microfluidics, *Nature protocols* 12 (1) (2017) 44.
- [418] A.M. Klein, L. Mazutis, I. Akartuna, N. Tallapragada, A. Veres, V. Li, L. Peshkin, D.A. Weitz, M.W. Kirschner, Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells, *Cell* 161 (5) (2015) 1187–1201.
- [419] B. Francz, R. Ungai-Salánki, É. Sautner, R. Horvath, B. Szabó, Subnanoliter precision piezo pipette for single-cell isolation and droplet printing, *Microfluidics and Nanofluidics* 24 (2) (2020) 12.
- [420] E. Brouzes, M. Medkova, N. Savenelli, D. Marran, M. Twardowski, J.B. Hutchison, J.M. Rothberg, D.R. Link, N. Perrimon, M.L. Samuels, Droplet microfluidic technology for single-cell high-throughput screening, *Proceedings of the National Academy of Sciences* 106 (34) (2009) 14195–14200.
- [421] Y. Yuan, J. Bouchon, M. Calvo-Calle, J. Xia, X. Zhang, L. Sun, F. Ye, D.A. Weitz, J.A. Heyman, Droplet encapsulation improves accuracy of immune cell cytokine capture assays, *Lab on a Chip* (2020).
- [422] C.W. Pan, D.G. Horvath, S. Braza, T. Moore, A. Lynch, C. Feit, P. Abhyad, Sorting by interfacial tension (SIFT): label-free selection of live cells based on single-cell metabolism, *Lab on a Chip* 19 (8) (2019) 1344–1351.
- [423] D. Vallejo, A. Nikoosmanzar, B.M. Paegel, J.C. Chaput, Fluorescence-activated droplet sorting for single-cell directed evolution, *ACS synthetic biology* 8 (6) (2019) 1430–1440.
- [424] M. Witek, I. Freed, S.A. Soper, Cell Separations and Sorting, *Analytical Chemistry* (2020).
- [425] C.W. Shields IV, C.D. Reyes, G.P. López, Microfluidic cell sorting: a review of the advances in the separation of cells from debulking to rare cell isolation, *Lab on a Chip* 15 (5) (2015) 1230–1249.
- [426] K. Matuła, F. Rivello, W.T. Huck, Single-Cell Analysis Using Droplet Microfluidics, *Advanced Biosystems* 4 (1) (2020) 1900188.
- [427] K. Doufène, C. Tourné-Péteilh, P. Etienne, A. Aubert-Pouëssel, Microfluidic Systems for Droplet Generation in Aqueous Continuous Phases: A Focus Review, *Langmuir* 35 (39) (2019) 12597–12612.
- [428] P. Zhu, L. Wang, Passive and active droplet generation with microfluidics: a review, *Lab on a Chip* 17 (1) (2017) 34–75.
- [429] S.-Y. Teh, R. Lin, L.-H. Hung, A.P. Lee, Droplet microfluidics, *Lab on a Chip* 8 (2) (2008) 198–220.
- [430] L. Rosenfeld, T. Lin, R. Derda, S.K. Tang, Review and analysis of performance metrics of droplet microfluidics systems, *Microfluidics and nanofluidics* 16 (5) (2014) 921–939.
- [431] H.-D. Xi, H. Zheng, W. Guo, A.M. Gañán-Calvo, Y. Ai, C.-W. Tsao, J. Zhou, W. Li, Y. Huang, N.-T. Nguyen, Active droplet sorting in microfluidics: a review, *Lab on a Chip* 17 (5) (2017) 751–771.
- [432] P. Sajeesh, A.K. Sen, Particle separation and sorting in microfluidic devices: a review, *Microfluidics and nanofluidics* 17 (1) (2014) 1–52.
- [433] Y.-C. Tan, Y.L. Ho, A.P. Lee, Microfluidic sorting of droplets by size, *Microfluidics and Nanofluidics* 4 (4) (2008) 343.
- [434] Y.-C. Tan, J.S. Fisher, A.I. Lee, V. Cristini, A.P. Lee, Design of microfluidic channel geometries for the control of droplet volume, chemical concentration, and sorting, *Lab on a Chip* 4 (4) (2004) 292–298.
- [435] X. Niu, M. Zhang, S. Peng, W. Wen, P. Sheng, Real-time detection, control, and sorting of microfluidic droplets, *Biomicrofluidics* 1 (4) (2007) 044101.
- [436] S. Hasan, D. Geissler, K. Wink, A. Hagen, J.J. Heiland, D. Belder, Fluorescence lifetime-activated droplet sorting in microfluidic chip systems, *Lab on a Chip* 19 (3) (2019) 403–409.
- [437] A. Sciambi, A.R. Abate, Accurate microfluidic sorting of droplets at 30 kHz, *Lab on a Chip* 15 (1) (2015) 47–51.
- [438] J.-C. Baret, O.J. Miller, V. Taly, M. Ryckelynck, A. El-Harrak, L. Frenz, C. Rick, M.L. Samuels, J.B. Hutchison, J.J. Agresti, Fluorescence-activated droplet sorting (FADS): efficient microfluidic cell sorting based on enzymatic activity, *Lab on a Chip* 9 (13) (2009) 1850–1858.
- [439] T.P. Lagus, J.F. Edd, A review of the theory, methods and recent applications of high-throughput single-cell droplet microfluidics, *J. Phys. D: Appl. Phys.* 46 (11) (2013) 114005.
- [440] N. Shembekar, H. Hu, D. Eustace, C.A. Merten, Single-cell droplet microfluidic screening for antibodies specifically binding to target cells, *Cell reports* 22 (8) (2018) 2206–2215.
- [441] V. Yelleswarapu, J.R. Buser, M. Haber, J. Baron, E. Inapuri, D. Issadore, Mobile platform for rapid sub-picoliter-per-milliliter, multiplexed, digital droplet detection of proteins, *Proceedings of the National Academy of Sciences* 116 (10) (2019) 4489–4495.
- [442] M. Shojaeian, F.-X. Lehr, H.U. Göringer, S. Hardt, On-demand production of femtoliter drops in microchannels and their use as biological reaction compartments, *Analytical chemistry* 91 (5) (2019) 3484–3491.
- [443] N. Sinha, N. Subedi, J. Tel, Integrating immunology and microfluidics for single immune cell analysis, *Frontiers in immunology* 9 (2018) 2373.
- [444] J. Sánchez Barea, J. Lee, D.-K. Kang, Recent Advances in Droplet-based Microfluidic Technologies for Biochemistry and Molecular Biology, *Micromachines* 10 (6) (2019) 412.
- [445] M. Linhult, S. Gulich, S. Hober, Affinity ligands for industrial protein purification, *Protein and peptide letters* 12 (4) (2005) 305–310.
- [446] E.R. Main, A.R. Lowe, S.G. Mochrie, S.E. Jackson, L. Regan, A recurring theme in protein engineering: the design, stability and folding of repeat proteins, *Current opinion in structural biology* 15 (4) (2005) 464–471.
- [447] D. Stroumpoulis, H. Zhang, L. Rubalcava, J. Gliem, M. Tirrell, Cell adhesion and growth to peptide-patterned supported lipid membranes, *Langmuir* 23 (7) (2007) 3849–3856.
- [448] G. Kaur, C. Wang, J. Sun, Q. Wang, The synergistic effects of multivalent ligand display and nanotopography on osteogenic differentiation of rat bone marrow stem cells, *Biomaterials* 31 (22) (2010) 5813–5824.
- [449] D. Zhang, Peptide microarrays for the discovery of cell-ligand interactions that direct cell state, University of Illinois at Urbana-Champaign (2016).
- [450] K.L. Melmon, Y. Weinstein, G. Shearer, H.R. Bourne, S. Bauminger, Separation of specific antibody-forming mouse cells by their adherence to insolubilized endogenous hormones, *Journal of Clinical Investigation* 53 (1) (1974) 22.
- [451] G. Shearer, Y. Weinstein, K.L. Melmon, Enhancement of immune response potential of mouse lymphoid cells fractionated over insolubilized conjugated histamine columns, *The Journal of Immunology* 113 (2) (1974) 597–607.
- [452] Y. Weinstein, K. Melmon, Control of immune responses by cyclic AMP and lymphocytes that adhere to histamine columns, *Immunological communications* 5 (5) (1976) 401–416.
- [453] G. Shearer, Y. Weinstein, K. Melmon, H. Bourne, Separation of leukocytes by their amine receptors: subsequent immunologic functions, *Cyclic AMP, cell growth, and the immune response*, Springer, 1974, pp. 135–146.
- [454] K. Melmon, Y. Weinstein, G. Shearer, H. Bourne, Leukocyte separation on the basis of their receptors for biogenic amines and prostaglandins: relation of the receptor to antibody formation, *Cyclic AMP, Cell Growth, and the Immune Response*, Springer, 1974, pp. 114–134.
- [455] G. SHEARER, H. BOURNE, LEUKOCYTE SEPARATION ON THE BASIS OF THEIR RECEPTORS FOR BIOGENIC AMINES AND PROSTAGLANDINS: RELATION OF THE RECEPTOR TO ANTIBODY FORMATION, in: *Cyclic AMP, Cell Growth, and the Immune Response: Proceedings of the Symposium Held at Marco Island, Florida January 8–10, 1973*, Springer Science & Business Media, 2013, p. 114.
- [456] M.L. Van Tassel, N.P. Price, M.J. Miller, Glycan-specific whole cell affinity chromatography: A versatile microbial adhesion platform, *MethodsX* 1 (2014) 244–250.
- [457] D.N. Krag, G.S. Shukla, G.-P. Shen, S. Pero, T. Ashikaga, S. Fuller, D.L. Weaver, S. Burdette-Radoux, C. Thomas, Selection of tumor-binding ligands in cancer patients with phage display libraries, *Cancer research* 66 (15) (2006) 7724–7733.
- [458] R. Stoltenburg, C. Reinemann, B. Strehlitz, SELEX—aevolutionary method to generate high-affinity nucleic acid ligands, *Biomolecular engineering* 24 (4) (2007) 381–403.
- [459] S.J. Wrenn, R.M. Weisinger, D.R. Halpin, P.B. Harbury, Synthetic ligands discovered by in vitro selection, *Journal of the American Chemical Society* 129 (43) (2007) 13137–13143.
- [460] H. Gohlke, G. Klebe, Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors, *Angewandte Chemie International Edition* 41 (15) (2002) 2644–2676.
- [461] T. Oyama, K.F. Sykes, K.N. Samli, J.D. Minna, S.A. Johnston, K.C. Brown, Isolation of lung tumor specific peptides from a random peptide library: generation of diagnostic and cell-targeting reagents, *Cancer letters* 202 (2) (2003) 219–230.
- [462] M.J. McGuire, K.N. Samli, S.A. Johnston, K.C. Brown, In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo, *Journal of molecular biology* 342 (1) (2004) 171–182.
- [463] V. Askoylakakis, S. Zitzmann, W. Mier, K. Graham, S. Krämer, F. von Wegner, R.H. Fink, M. Schwab, M. Eisenhut, U. Haberkorn, Preclinical evaluation of the breast cancer cell-binding peptide, p160, *Clinical cancer research* 11 (18) (2005) 6705–6712.
- [464] K. Guo, H.P. Wendel, L. Scheideler, G. Ziemer, A.M. Scheule, Aptamer-based capture molecules as a novel coating strategy to promote cell adhesion, *Journal of cellular and molecular medicine* 9 (3) (2005) 731–736.
- [465] M.J. McGuire, K.N. Samli, Y.-C. Chang, K.C. Brown, Novel ligands for cancer diagnosis: selection of peptide ligands for identification and isolation of B-cell lymphomas, *Experimental hematology* 34 (4) (2006) 443–452.
- [466] T. Oyama, I.T. Rombel, K.N. Samli, X. Zhou, K.C. Brown, Isolation of multiple cell-binding ligands from different phage displayed-peptide libraries, *Biosensors and Bioelectronics* 21 (10) (2006) 1867–1875.
- [467] A. Lo, C.-T. Lin, H.-C. Wu, Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery, *Molecular cancer therapeutics* 7 (3) (2008) 579–589.
- [468] M.J. McGuire, S. Li, K.C. Brown, Biopanning of phage displayed peptide libraries for the isolation of cell-specific ligands, *Biosensors and Biotechnology: Methods and Protocols: Electrochemical and Mechanical Detectors, Lateral Flow and Ligands for Biosensors* (2009) 291–321.
- [469] A.A. Nery, C. Wrenger, H. Ulrich, Recognition of biomarkers and cell-specific molecular signatures: Aptamers as capture agents, *Journal of separation science* 32 (10) (2009) 1523–1530.
- [470] N. Svensen, J.J. Díaz-Mochón, M. Bradley, Encoded peptide libraries and the discovery of new cell binding ligands, *Chemical Communications* 47 (27) (2011) 7638–7640.
- [471] K. Sefah, D. Shangguan, X. Xiong, M.B. O'donoghue, W. Tan, Development of DNA aptamers using Cell-SELEX, *Nature protocols* 5 (6) (2010) 1169–1185.
- [472] S. Ohuchi, Cell-SELEX technology, *BioResearch open access* 1 (6) (2012) 265–272.
- [473] J. Moon, G. Kim, S.B. Park, J. Lim, C. Mo, Comparison of whole-cell SELEX methods for the identification of *Staphylococcus aureus*-specific DNA aptamers, *Sensors* 15 (4) (2015) 8884–8897.
- [474] A. Ganji, A. Varasteh, M. Sankian, Aptamers: new arrows to target dendritic cells, *Journal of drug targeting* 24 (1) (2016) 1–12.

- [475] Y. Xu, J.A. Phillips, J. Yan, Q. Li, Z.H. Fan, W. Tan, Aptamer-based microfluidic device for enrichment, sorting, and detection of multiple cancer cells, *Analytical chemistry* 81 (17) (2009) 7436–7442.
- [476] Z. Zhang, N. Chen, S. Li, M.R. Battig, Y. Wang, Programmable hydrogels for controlled cell catch and release using hybridized aptamers and complementary sequences, *Journal of the American Chemical Society* 134 (38) (2012) 15716–15719.
- [477] D. Pappas, K. Wang, Cellular separations: a review of new challenges in analytical chemistry, *Analytica chimica acta* 601 (1) (2007) 26–35.
- [478] Y. Chen, D. Tyagi, M. Lyu, A.J. Carrier, C. Nganou, B. Youden, W. Wang, S. Cui, M. Servos, K. Oakes, Regenerative NanoOctopus Based on Multivalent-Aptamer-Functionalized Magnetic Microparticles for Effective Cell Capture in Whole Blood, *Analytical chemistry* 91 (6) (2019) 4017–4022.
- [479] Z. Li, G. Wang, Y. Shen, N. Guo, N. Ma, DNA-templated magnetic nanoparticle-quantum dot polymers for ultrasensitive capture and detection of circulating tumor cells, *Advanced Functional Materials* 28 (14) (2018) 1707152.
- [480] J. Feng, Z. Dai, X. Tian, X. Jiang, Detection of *Listeria monocytogenes* based on combined aptamers magnetic capture and loop-mediated isothermal amplification, *Food Control* 85 (2018) 443–452.
- [481] W. Sheng, T. Chen, R. Kamath, X. Xiong, W. Tan, Z.H. Fan, Aptamer-enabled efficient isolation of cancer cells from whole blood using a microfluidic device, *Analytical chemistry* 84 (9) (2012) 4199–4206.
- [482] Q. Zhou, Y. Liu, D.-S. Shin, J. Silangcruz, N. Tuleuova, A. Revzin, Aptamer-containing surfaces for selective capture of CD4 expressing cells, *Langmuir* 28 (34) (2012) 12544–12549.
- [483] L. Liu, K. Yang, H. Gao, X. Li, Y. Chen, L. Zhang, X. Peng, Y. Zhang, Artificial antibody with site-enhanced multivalent aptamers for specific capture of circulating tumor cells, *Analytical chemistry* 91 (4) (2019) 2591–2594.
- [484] Q. Zhu, G. Liu, M. Kai, DNA aptamers in the diagnosis and treatment of human diseases, *Molecules* 20 (12) (2015) 20979–20997.
- [485] J.W. Yoon, I.H. Jang, S.C. Heo, Y.W. Kwon, E.J. Choi, K.-H. Bae, D.-S. Suh, S.-C. Kim, S. Han, S. Haam, Isolation of Foreign Material-Free Endothelial Progenitor Cells Using CD31 Aptamer and Therapeutic Application for Ischemic Injury, *PLoS one* 10 (7) (2015) e0131785.
- [486] A.D. Keefe, S. Pai, A. Ellington, Aptamers as therapeutics, *Nature reviews Drug discovery* 9 (7) (2010) 537–550.
- [487] A.N. Veleva, D.B. Nepal, C.B. Frederick, J. Schwab, P. Lockyer, H. Yuan, D.S. Lalush, C. Patterson, Efficient in vivo selection of a novel tumor-associated peptide from a phage display library, *Molecules* 16 (1) (2011) 900–914.
- [488] J.H. Choi, W.K. Lee, S.H. Han, S. Ha, S.M. Ahn, J.S. Kang, Y.J. Choi, C.-H. Yun, Identification and characterization of nonapeptide targeting a human B cell lymphoma, *Raji*, *International immunopharmacology* 8 (6) (2008) 852–858.
- [489] H. Wang, C. Ma, R. Li, Y. Guo, Y. He, X. Wang, Y. Chen, Y. Hou, Selection and characterization of colorectal cancer cell-specific peptides, *Biotechnology letters* 35 (5) (2013) 671–677.
- [490] J. De, Y.-C. Chang, K.N. Samli, J.C. Schisler, C.B. Newgard, S.A. Johnston, K.C. Brown, Isolation of a Mycoplasma-specific binding peptide from an unbiased phage-displayed peptide library, *Molecular Biosystems* 1 (2) (2005) 149–157.
- [491] M. Hasenbein, T. Andersen, R. Bizios, Micropatterned surfaces modified with select peptides promote exclusive interactions with osteoblasts, *Biomaterials* 23 (19) (2002) 3937–3942.
- [492] B.D. Plouffe, D.N. Njoka, J. Harris, J. Liao, N.K. Horick, M. Radisic, S.K. Murthy, Peptide-mediated selective adhesion of smooth muscle and endothelial cells in microfluidic shear flow, *Langmuir* 23 (9) (2007) 5050–5055.
- [493] B.D. Plouffe, M. Radisic, S.K. Murthy, Microfluidic depletion of endothelial cells, smooth muscle cells, and fibroblasts from heterogeneous suspensions, *Lab on a Chip* 8 (3) (2008) 462–472.
- [494] D.A. Vickers, S.K. Murthy, Receptor expression changes as a basis for endothelial cell identification using microfluidic channels, *Lab on a Chip* 10 (18) (2010) 2380–2386.
- [495] J.S. Nielsen, K.M. McNagny, Novel functions of the CD34 family, *Journal of cell science* 121 (22) (2008) 3683–3692.
- [496] A.H. Yin, S. Miraglia, E.D. Zanjani, G. Almeida-Porada, M. Ogawa, A.G. Leary, J. Olweus, J. Kearney, D.W. Buck, AC133, a novel marker for human hematopoietic stem and progenitor cells, *Blood* 90 (12) (1997) 5002–5012.
- [497] J. Sun, C. Zhang, G. Liu, H. Liu, C. Zhou, Y. Lu, C. Zhou, L. Yuan, X. Li, A novel mouse CD133 binding-peptide screened by phage display inhibits cancer cell motility in vitro, *Clinical & experimental metastasis* 29 (3) (2012) 185–196.
- [498] K. Mehta, U. Shahid, F. Malavasi, Human CD38, a cell-surface protein with multiple functions, *The FASEB Journal* 10 (12) (1996) 1408–1417.
- [499] T. Ulyanova, L.M. Scott, G.V. Priestley, Y. Jiang, B. Nakamoto, P.A. Koni, T. Papayannopoulou, VCAM-1 expression in adult hematopoietic and non-hematopoietic cells is controlled by tissue-inductive signals and reflects their developmental origin, *Blood* 106 (1) (2005) 86–94.
- [500] S. Shukla, M.A. Langley, J. Singh, J.M. Edgar, M. Mohtashami, J.C. Zúñiga-Pflücker, P.W. Zandstra, Progenitor T-cell differentiation from hematopoietic stem cells using Delta-like-4 and VCAM-1, *Nature Methods* (2017).
- [501] K. Leung, VHPKQHRGSGKGC-liquid perfluorocarbon nanoparticles, National Center for Biotechnology Information (US), BethesdaMD, 2004.
- [502] W. Xu, S. Zhang, Q. Zhou, W. Chen, VHPKQHR peptide modified magnetic mesoporous nanoparticles for MRI detection of atherosclerosis lesions, *Artificial cells, nanomedicine, and biotechnology* 47(1) (2019) 2440–2448.
- [503] S. Lyman, K. Brasel, A. Rousseau, D. Williams, The flt3 ligand: a hematopoietic stem cell factor whose activities are distinct from steel factor, *Stem cells* (Dayton, Ohio) 12 (1993) 99–107 discussion 108–10.
- [504] S. Tima, S. Okonogi, C. Ampasavate, C. Pickens, C. Berkland, S. Anuchapreeda, Development and characterization of FLT3-specific curcumin-loaded polymeric micelles as a drug delivery system for treating FLT3-overexpressing leukemic cells, *Journal of pharmaceutical sciences* 105 (12) (2016) 3645–3657.
- [505] K. Bacon, M. Burroughs, A. Blain, S. Menegatti, B.M. Rao, Screening yeast display libraries against magnetized yeast cell targets enables efficient isolation of membrane protein binders, *ACS combinatorial science* 21 (12) (2019) 817–832.
- [506] L. Terstappen, S. Huang, Analysis of bone marrow stem cell, *Blood cells* 20 (1) (1993) 45–61 discussion 61–3.
- [507] M. Kondo, I.L. Weissman, K. Akashi, Identification of clonogenic common lymphoid progenitors in mouse bone marrow, *Cell* 91 (5) (1997) 661–672.
- [508] M. Bhatia, D. Bonnet, B. Murdoch, O.I. Gan, J.E. Dick, A newly discovered class of human hematopoietic cells with SCID-repopulating activity, *Nature medicine* 4 (9) (1998) 1038–1045.
- [509] Y. Guo, M. Lübbert, M. Engelhardt, CD34– hematopoietic stem cells: current concepts and controversies, *Stem cells* 21 (1) (2003) 15–20.
- [510] H. Karsunky, M. Merad, A. Cuzzo, I.L. Weissman, M.G. Manz, Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo, *Journal of Experimental Medicine* 198 (2) (2003) 305–313.
- [511] A.Y. Lai, M. Kondo, Asymmetrical lymphoid and myeloid lineage commitment in multipotent hematopoietic progenitors, *Journal of Experimental Medicine* 203 (8) (2006) 1867–1873.
- [512] H.E. Broxmeyer, Umbilical cord transplantation: epilogue, *Seminars in hematology*, Elsevier, 2010, pp. 97–103.
- [513] J. Seita, I.L. Weissman, Hematopoietic stem cell: self-renewal versus differentiation, *Wiley Interdisciplinary Reviews: Systems Biology and Medicine* 2 (6) (2010) 640–653.
- [514] S.W. Boyer, A.V. Schroeder, S. Smith-Berdan, E.C. Forsberg, All hematopoietic cells develop from hematopoietic stem cells through Flk2/Flt3-positive progenitor cells, *Cell stem cell* 9 (1) (2011) 64–73.
- [515] S.W. Boyer, A.E. Beaudin, E.C. Forsberg, Mapping differentiation pathways from hematopoietic stem cells using Flk2/Flt3 lineage tracing, *Cell Cycle* 11 (17) (2012) 3180–3188.
- [516] C.J. Eaves, Hematopoietic stem cells: concepts, definitions, and the new reality, *Blood* 125 (17) (2015) 2605–2613.
- [517] G. Volpe, M. Clarke, P. García, D.S. Walton, A. Vegiopoulos, W. Del Pozzo, L.P. O'Neill, J. Frampton, S. Dumon, Regulation of the Flt3 Gene in haematopoietic stem and early progenitor cells, *PLoS one* 10 (9) (2015) e0138257.
- [518] K. Day, J.D. Schneible, A.T. Young, V.A. Pozdin, L.S. Gaffney, R. Prodromou, D. Freytes, M. Daniele, S. Menegatti, Photoinduced reconfiguration to control the protein-binding affinity of azobenzene-cyclized peptides, *Journal of Materials Chemistry B* (2020). <https://pubs.rsc.org/en/content/articlelanding/2020/tb/d0tb01189d#1divAbstract>.
- [519] I. Zebger, M. Rutloh, U. Hoffmann, J. Stumpe, H. Siesler, S. Hvilsted, Photoorientation of a liquid crystalline polyester with azobenzene side groups. 1. Effects of irradiation with linearly polarized blue light, *The Journal of Physical Chemistry A* 106 (14) (2002) 3454–3462.
- [520] O. Sadovskis, A.A. Beharry, F. Zhang, G.A. Woolley, Spectral tuning of azobenzene photoswitches for biological applications, *Angewandte Chemie International Edition* 48 (8) (2009) 1484–1486.
- [521] A.A. Beharry, O. Sadovskis, G.A. Woolley, Azobenzene photoswitching without ultraviolet light, *Journal of the American Chemical Society* 133 (49) (2011) 19684–19687.
- [522] S. Samanta, A.A. Beharry, O. Sadovskis, T.M. McCormick, A. Babalhavaeji, V. Tropepe, G.A. Woolley, Photoswitching azo compounds in vivo with red light, *Journal of the American Chemical Society* 135 (26) (2013) 9777–9784.
- [523] L. Zhang, H. Zhang, F. Gao, H. Peng, Y. Ruan, Y. Xu, W. Weng, Host–guest interaction between fluoro-substituted azobenzene derivative and cyclodextrins, *RSC Advances* 5 (16) (2015) 12007–12014.
- [524] M.J. Hansen, M.M. Lerch, W. Szymanski, B.L. Feringa, Direct and Versatile Synthesis of Red-Shifted Azobenzenes, *Angewandte Chemie* 128 (43) (2016) 13712–13716.
- [525] B.J. Ravenhill, L. Sodaj, J. Houghton, R. Antrobus, M.P. Weekes, Comprehensive cell surface proteomics defines markers of classical, intermediate and non-classical monocytes, *Scientific reports* 10 (1) (2020) 1–11.